[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4474
1. Lin E, Boire A, Hemmige V, Husain AN, Sorrentino M, Nathan S, Akhter SA, Dickstein J, Archer SL: Cardiac tamponade mimicking tuberculous pericarditis as the initial presentation of chronic lymphocytic leukemia in a 58-year-old woman: a case report. J Med Case Rep; 2010;4:246
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade mimicking tuberculous pericarditis as the initial presentation of chronic lymphocytic leukemia in a 58-year-old woman: a case report.
  • INTRODUCTION: Chronic lymphocytic leukemia is an indolent disease that often presents with complaints of lymphadenopathy or is detected as an incidental laboratory finding.
  • It is rarely considered in the differential diagnosis of patients presenting with tamponade or a large, bloody pericardial effusion.
  • However, the signs, symptoms and laboratory findings of pericarditis related to chronic lymphocytic leukemia can mimic tuberculosis.
  • CASE PRESENTATION: We report the case of a 58-year-old African American-Nigerian woman with a history of travel to Nigeria and a positive tuberculin skin test who presented with cardiac tamponade.
  • Assessment of blood by flow cytometry and pericardial biopsy by immunohistochemistry revealed CD5 (+) and CD20 (+) lymphocytes in both tissues, demonstrating this to be an unusual manifestation of early stage chronic lymphocytic leukemia.
  • CONCLUSION: Although most malignancies that involve the pericardium clinically manifest elsewhere before presenting with tamponade, this case illustrates the potential for early stage chronic lymphocytic leukemia to present as a large pericardial effusion with tamponade.
  • This case also demonstrates that it is possible to treat chronic lymphocytic leukemia-related pericardial tamponade by removal of the fluid without chemotherapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1979 Oct;67(4):719-23 [495642.001]
  • [Cites] Postgrad Med J. 1989 Oct;65(768):773-5 [2616408.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):322-4 [6574803.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] Postgrad Med J. 1994 Oct;70(828):703-7 [7831164.001]
  • [Cites] Heart. 1996 Jan;75(1):67-71 [8624876.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):829-32 [17454648.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1168-9 [9426341.001]
  • [Cites] Chest. 1999 Dec;116(6):1564-9 [10593777.001]
  • [Cites] Am J Med. 2001 Oct 15;111(6):504-5 [11690583.001]
  • [Cites] Am J Cardiol. 2005 Jun 1;95(11):1393-4 [15904655.001]
  • [Cites] Acta Trop. 2006 Aug;99(1):67-74 [16950165.001]
  • [Cites] Clin Lab Haematol. 1996 Jun;18(2):117-9 [8866146.001]
  • (PMID = 20684780.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2923171
  •  go-up   go-down


2. Mohn A, Di Marzio D, De Berardiniis A, Di Marzio A, Capanna R, Fioritoni G, Chiarelli F: Long-term follow-up of children treated for acute lymphoblastic leukemia and the recovery of beta-cell function. Haematologica; 2006 Oct;91(10):1424-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of children treated for acute lymphoblastic leukemia and the recovery of beta-cell function.
  • We studied the evolution of beta-cell function in 32 children treated for acute lymphoblastic leukemia (ALL) through a long-term follow-up after completion of therapy.
  • [MeSH-major] Insulin-Secreting Cells / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recovery of Function / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2006 Dec;91(12 Suppl):ELT12; author reply ELT13 [17194672.001]
  • (PMID = 16963397.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] Italy
  •  go-up   go-down


3. van Tilburg CM, Sanders EA, Rovers MM, Wolfs TF, Bierings MB: Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia; 2006 Oct;20(10):1717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review.
  • Intensified chemotherapy regimens resulting in improved survival of children with acute lymphocytic leukemia (ALL) lead to concerns about therapy-induced immune damage reflected by the loss of protection of previous immunizations and the efficacy of (re-)vaccination.
  • [MeSH-major] Antibodies / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Vaccination. Vaccines / immunology

  • MedlinePlus Health Information. consumer health - Immunization.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16888619.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Vaccines
  • [Number-of-references] 48
  •  go-up   go-down


Advertisement
4. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A: [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004]. Rev Epidemiol Sante Publique; 2009 Jun;57(3):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Epidémiologie des hémopathies malignes en Basse-Normandie.
  • We extracted the data from the "Registre régional des hémopathies malignes de Basse-Normandie (RRHMBN)", a French registry which belongs to the Association of the French Cancer Registries (FRANCIM).
  • All the malignant haematological diseases were coded using the third edition of the International Classification for Oncologic Diseases (ICD-O-3) and the ADICAP classification, a special version adapted in 2001 for haematology.
  • Five thousand five hundred and ten new cases of malignant haematological disorders were registered over the period 1997-2004.
  • In men, the more frequent malignant disorders were non-Hodgkin's malignant lymphomas (NHML) followed by chronic lymphocytic leukemia and other mature neoplasms, myelodysplastic syndromes (MDS), multiple myeloma (MM), myeloproliferative disorders (MPD), acute myeloid leukemias (AML), Hodgkin's lymphomas (HL), Waldenström's macroglobulinemia (WM) and acute lymphoblastic leukemia (ALL).
  • In women, MM is the third more frequent haematological disorders after NHML and lymphocytic leukaemia and other mature neoplasms, MPD, MDS, AML, Hodgkin's lymphomas, WM and ALL.
  • We provide the incidence for the main haematological disorders and for the first time we also present the incidence of the different subtypes of the Hodgkin's and non-Hodgkin's malignant lymphomas, mature lymphoid neoplasms, MPD and also MDS.
  • A high quality of the collected data remains necessary for a continuous watching and research on patients with malignant haematological diseases.
  • [MeSH-minor] Adult. Aged. Algorithms. Female. France / epidemiology. Hodgkin Disease / epidemiology. Humans. Incidence. International Classification of Diseases / statistics & numerical data. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Medical Records. Middle Aged. Multiple Myeloma / epidemiology. Myelodysplastic Syndromes / epidemiology. Myeloproliferative Disorders / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Retrospective Studies. Waldenstrom Macroglobulinemia / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375876.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M: Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst; 2006 Oct 4;98(19):1363-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
  • BACKGROUND: Proteomic investigations have revealed alterations in cytoskeletal proteins expressed in human acute lymphoblastic leukemia cells that are resistant to microtubule-disrupting agents.
  • We characterized gamma-actin expression in antimicrotubule drug-resistant leukemia and examined the effect of altered gamma-actin in resistance of acute lymphoblastic leukemia to antimicrotubule agents.
  • METHODS: Two-dimensional polyacrylamide gel electrophoresis and mass spectrometry were used to identify actin proteins in human acute lymphoblastic leukemia cell lines resistant to vinblastine (CCRF-CEM/VLB100 cells) and desoxyepothilone B (CCRF-CEM/dEpoB140 cells).
  • Expression of gamma-actin (normalized to that of beta2-microglobulin [beta2M]) in primary leukemia cells obtained from patients at diagnosis (n = 44) and relapse (n = 25) was examined using semiquantitative reverse transcription-polymerase chain reaction.
  • Statistical significance of changes in the ratio of gamma-actin to beta2M expression between diagnosis and relapse samples was determined by two-sided unpaired Student's t tests.
  • No gamma-actin gene mutations were identified in 37 samples of primary leukemia cells (eight from patients at diagnosis, 29 from patients at relapse).
  • Gamma-actin gene expression was lower in acute lymphoblastic leukemia samples collected at clinical relapse (n = 25; mean gamma-actin/beta2M = 0.53) than in samples collected at diagnosis (n = 44; mean gamma-actin/beta2M = 0.68; difference = 0.15, 95% confidence interval [CI] = 0.04 to 0.27, P = .01).
  • CONCLUSIONS: These data provide functional and associative clinical evidence of a novel form of drug resistance that involves interactions between gamma-actin and microtubules.
  • [MeSH-major] Actins / drug effects. Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm / drug effects. Microtubules / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Tubulin / drug effects. Tubulin Modulators / pharmacology
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Child. DNA Mutational Analysis. Electrophoresis, Gel, Two-Dimensional. Epothilones / pharmacology. Fluorescent Antibody Technique, Indirect. Gene Expression Regulation, Neoplastic / drug effects. Gene Silencing / drug effects. Humans. Leucine. Mass Spectrometry. Mice. Mutation / drug effects. Neuroblastoma / drug therapy. Neuroblastoma / metabolism. Plasmids. Proline. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Stem Cell Assay. Valine. Vinblastine / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • Hazardous Substances Data Bank. L-Valine .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Oct 4;98(19):1345-7 [17018774.001]
  • (PMID = 17018783.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antineoplastic Agents; 0 / Epothilones; 0 / RNA, Small Interfering; 0 / Tubulin; 0 / Tubulin Modulators; 0 / desoxyepothilone B; 5V9KLZ54CY / Vinblastine; 9DLQ4CIU6V / Proline; GMW67QNF9C / Leucine; HG18B9YRS7 / Valine
  •  go-up   go-down


6. Krappmann P, Paulides M, Stöhr W, Ittner E, Plattig B, Nickel P, Lackner H, Schrappe M, Janka G, Beck JD, Langer T: Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. Pediatr Hematol Oncol; 2007 Mar;24(2):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up.
  • Sixty-six patients (mean age at diagnosis 7.9 +/- 3.6 years, 34 female), treated with repeated intrathecal and systemical methotrexate administrations without cranial irradiation, underwent psychometric testing for intelligence, concentration, and visual-motor integration postdiagnosis and after reinduction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cognition Disorders / chemically induced. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454775.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


7. Malinowska K, Modranka R, Kubiak K, Mrowicka M, Klimczak A, Kedziora J, Rutkowski M: [Testing antineoplastic activity of new platinum(II) and palladium(II) complex compounds]. Pol Merkur Lekarski; 2009 Jan;26(151):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antineoplastic activity of the new complex compounds--pyrazole derivatives with Pt(II) and Pd(II) ions was tested on mouse L1210 leukemia cell culture and on lymphatic leukemia P388.
  • RESULTS: Complexes 13, 21, 25, 16, 24 and 28 did not reveal any antineoplastic activity to the mouse L1210 leukemia, whereas complexes 13, 21 and 25 revealed in-vivo antineoplastic activity to the P388 leukemia, extending the mouse's survival time by about 50%.
  • CONCLUSIONS: As a result of the tests conducted to asses the in-vivo antineoplastic activity it was found that the 25 complex demonstrates the strongest activity to the P388 leukemia.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia L1210 / drug therapy. Leukemia P388 / drug therapy. Organoplatinum Compounds / pharmacology
  • [MeSH-minor] Animals. Cell Line. Cisplatin / pharmacology. Mice. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391509.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Kesminiene A, Evrard AS, Ivanov VK, Malakhova IV, Kurtinaitis J, Stengrevics A, Tekkel M, Anspaugh LR, Bouville A, Chekin S, Chumak VV, Drozdovitch V, Gapanovich V, Golovanov I, Hubert P, Illichev SV, Khait SE, Kryuchkov VP, Maceika E, Maksyoutov M, Mirkhaidarov AK, Polyakov S, Shchukina N, Tenet V, Tserakhovich TI, Tsykalo A, Tukov AR, Cardis E: Risk of hematological malignancies among Chernobyl liquidators. Radiat Res; 2008 Dec;170(6):721-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case-control study of hematological malignancies was conducted among Chernobyl liquidators (accident recovery workers) from Belarus, Russia and Baltic countries to assess the effect of low- to medium-dose protracted radiation exposures on the relative risk of these diseases.
  • A total of 117 cases [69 leukemia, 34 non-Hodgkin lymphoma (NHL) and 14 other malignancies of lymphoid and hematopoietic tissue] and 481 matched controls were included in the study.
  • The main analyses were restricted to 70 cases (40 leukemia, 20 NHL and 10 other) and their 287 matched controls with reliable information on work in the Chernobyl area.
  • The corresponding estimate for leukemia excluding chronic lymphoid leukemia (CLL) was 0.50 (90% CI -0.38, 5.7).

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2007 Dec;139(5):672-86 [18021081.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):799-808 [17922878.001]
  • [Cites] Radiat Res. 2007 Dec;168(6):757-63 [18088178.001]
  • [Cites] Health Phys. 2009 Oct;97(4):275-98 [19741357.001]
  • [Cites] Int J Hematol. 2002 Jul;76(1):55-60 [12138896.001]
  • [Cites] Radiat Res. 2003 Oct;160(4):408-17 [12968933.001]
  • [Cites] Radiat Res. 2003 Oct;160(4):381-407 [12968934.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Radiat Res. 1996 Jul;146(1):1-27 [8677290.001]
  • [Cites] Radiats Biol Radioecol. 1996 Sep-Oct;36(5):747-57 [9019289.001]
  • [Cites] Radiat Res. 1997 May;147(5):653-7 [9146711.001]
  • [Cites] Radiat Environ Biophys. 1997 Sep;36(3):161-7 [9402632.001]
  • [Cites] Appl Radiat Isot. 2005 Feb;62(2):141-6 [15607440.001]
  • [Cites] Environ Health Perspect. 2005 Jan;113(1):1-5 [15626639.001]
  • [Cites] BMJ. 2005 Jul 9;331(7508):77 [15987704.001]
  • [Cites] Radiat Res. 2005 Nov;164(5):602-11 [16238437.001]
  • [Cites] J Radiol Prot. 2006 Mar;26(1):17-32 [16522942.001]
  • [Cites] Health Phys. 2006 Apr;90(4):312-27 [16538137.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):162-8 [16432838.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):158-67 [16808604.001]
  • [Cites] Radiat Res. 2007 Apr;167(4):396-416 [17388693.001]
  • (PMID = 19138033.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010133-13; United States / ODCDC CDC HHS / CC / IRO1/CC/R015763-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS215596; NLM/ PMC2904977
  •  go-up   go-down


9. Charafeddine KM, Hatoum HA, Otrock ZK, Mahfouz RA, Salem ZM, Shamseddine AI, Taher AT, El-Saghir NS, Bazarbachi A: Long-term outcome of adult acute lymphoblastic leukemia in Lebanon: a single institution experience from the American University of Beirut. Hematol Oncol Stem Cell Ther; 2009;2(2):333-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of adult acute lymphoblastic leukemia in Lebanon: a single institution experience from the American University of Beirut.
  • BACKGROUND AND OBJECTIVES: The most important studies about outcome of acute leukemia come from developed countries, whereas most of the patients with this disease are in developing countries.
  • We report predictive and prognostic factors in patients with acute lymphoblastic leukemia (ALL) in a tertiary care center in a developing country.
  • PATIENTS AND METHODS: We retrospectively reviewed the records of adult patients with acute leukemia who were referred to the American University of Beirut Medical Center between 1996 and early 2006.
  • Twenty-seven patients received intrathecal chemotherapy as prophylaxis (n=24) or as treatment for CNS disease (n=3).
  • The median disease-free survival (DFS) time was 12 months, while the five-year DFS was 38%.
  • CONCLUSION: Despite limitations and the relatively low socioeconomic status of the Lebanese population, OS (38%) and DFS (38%) are quite similar to international data.
  • Trends toward a higher CR and DFS in adults are due to intensified consolidation chemotherapy, the use of stem cell transplantation, and improvements in supportive care.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118056.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


10. Röösli M, Lörtscher M, Egger M, Pfluger D, Schreier N, Lörtscher E, Locher P, Spoerri A, Minder C: Leukaemia, brain tumours and exposure to extremely low frequency magnetic fields: cohort study of Swiss railway employees. Occup Environ Med; 2007 Aug;64(8):553-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia, brain tumours and exposure to extremely low frequency magnetic fields: cohort study of Swiss railway employees.
  • AIMS: To investigate the relationship between extremely low frequency magnetic field (ELF-MF) exposure and mortality from leukaemia and brain tumour in a cohort of Swiss railway workers.
  • Mortality rates for leukaemia and brain tumour of highly exposed train drivers (21 muT average annual exposure) were compared with medium and low exposed occupational groups (i.e. station masters with an average exposure of 1 muT).
  • RESULTS: The hazard ratio (HR) for leukaemia mortality of train drivers was 1.43 (95% CI 0.74 to 2.77) compared with station masters.
  • For myeloid leukaemia the HR of train drivers was 4.74 (95% CI 1.04 to 21.60) and for Hodgkin's disease 3.29 (95% CI 0.69 to 15.63).
  • Lymphoid leukaemia, non-Hodgkin's disease and brain tumour mortality were not associated with magnetic field exposure.
  • CONCLUSIONS: Some evidence of an exposure-response association was found for myeloid leukaemia and Hodgkin's disease, but not for other haematopoietic and lymphatic malignancies and brain tumours.
  • [MeSH-major] Brain Neoplasms / etiology. Electromagnetic Fields / adverse effects. Leukemia / etiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Railroads


11. Katamadze NA, Lartsuliani KP, Kiknadze MP: Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin. Georgian Med News; 2009 Jan;(166):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with malignant blood diseases (with non-Hodgkin's, Hodgkin's lymphoma and chronic lymphatic leukaemia) and patients with idiopathic dilated cardiomyopathy were investigated.
  • The first group included 49 patients (25 men and 24 women, average age was 41.2+/-2.1) with malignant blood diseases.


12. Kourti M, Tragiannidis A, Makedou A, Papageorgiou T, Rousso I, Athanassiadou F: Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol; 2005 Sep;27(9):499-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy.
  • The metabolic syndrome is a cluster of potent risk factors for cardiovascular diseases.
  • To provide information on the late complications of chemotherapy for acute lymphoblastic leukemia (ALL), the authors prospectively studied the frequency of overweight, obesity, and metabolic syndrome in survivors of ALL in the initial years after the completion of therapy.
  • Prompt recognition of the risk factors for metabolic syndrome and intervention seem mandatory to ensure early prevention of cardiovascular disease in survivors of ALL.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Metabolic Syndrome X / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


13. Wu S, Gessner R, von Stackelberg A, Kirchner R, Henze G, Seeger K: Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence. Cancer; 2005 Mar 1;103(5):1054-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence.
  • BACKGROUND: Recent studies have shown that cytokines/cytokine receptors (C/CR) affect leukemic cell growth and survival.
  • The goal of the current study was to investigate possible correlations between gene expression patterns of C/CR in leukemic cells, clinical features, and outcome in children with acute lymphoblastic leukemia (ALL) at first disease recurrence.
  • METHODS: Between January 1997 and December 2000, bone marrow (BM) samples were collected from 68 children with first ALL recurrence at diagnosis.
  • These patients were enrolled in the ALL-REZ 95-96 disease recurrence trials of the Berlin-Frankurt-Munster study group.
  • RESULTS: In comparison with T-lineage ALL specimens, expression of IL-10, IFN-gamma, IL-15Ralpha, and Flt1 was significantly higher in B-cell precursor (BCP) ALL specimens (P <0.01).
  • [MeSH-major] Cytokines / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cytokine / genetics
  • [MeSH-minor] Adolescent. Bone Marrow / chemistry. Cell Lineage. Child. Child, Preschool. Fluorescent Antibody Technique. Gene Expression. Humans. Infant. Male. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome


14. Tarello W: Lymphoid leukaemia in a saker falcon. Vet Rec; 2006 Feb 11;158(6):212
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoid leukaemia in a saker falcon.
  • [MeSH-major] Bird Diseases / diagnosis. Bird Diseases / therapy. Falconiformes. Leukemia, Lymphoid / veterinary

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474066.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenites; 0 / Potassium Compounds; 1332-10-1 / potassium arsenite solution
  •  go-up   go-down


15. Peková S, Bezdícková L, Smolej L, Kozák T, Hochová I, Zák P, Tomsíková L, Průcha M: Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology. Mol Diagn Ther; 2007;11(5):325-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology.
  • BACKGROUND: The knowledge of biological characteristics of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) remains sparse.
  • To address this issue in prospective studies, we have developed a quantitative molecular approach to monitor MRD in CLL, which allows the malignant clone to be traced with far higher sensitivity than possible with the techniques available currently.
  • Thirty patients were followed up molecularly for a median of 250 days (range 69-570 days).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm, Residual / genetics. Nucleic Acid Hybridization / methods. Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 2002 May;81(5):258-66 [12029535.001]
  • [Cites] Blood Cells. 1987;12(2):457-70 [3620708.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3433-8 [15809449.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):61-2 [9260583.001]
  • [Cites] Differentiation. 2005 Jul;73(6):261-77 [16138827.001]
  • [Cites] EMBO J. 2001 Aug 15;20(16):4570-6 [11500383.001]
  • [Cites] Leukemia. 2002 Jun;16(6):985-92 [12040430.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):309-17 [16856923.001]
  • [Cites] Mol Diagn. 2005;9(1):23-34 [16035732.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):245-51 [16321853.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:163-83 [15561682.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):455-62 [15160906.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4563-9 [16449533.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1630-6 [15295608.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4389-96 [16131571.001]
  • [Cites] Leuk Res. 1993 Aug;17(8):677-84 [8355512.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):42-59 [9482526.001]
  • [Cites] Blood. 2001 Jul 1;98(1):29-35 [11418459.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2850-8 [14670929.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • (PMID = 17963420.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Tumor Suppressor Protein p53; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


16. Foon KA, Hallek MJ: Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia; 2010 Mar;24(3):500-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing paradigms in the treatment of chronic lymphocytic leukemia.
  • Progress in our understanding of chronic lymphocytic leukemia and its treatment has resulted in a more tailored approach to patient management, with different therapeutic regimens for different patient populations.
  • Selection of appropriate initial therapy should be based primarily on patient characteristics such as age, performance status and the expected clinical course of the leukemia based on established risk factors.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033051.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents, Alkylating; 0 / Nitrogen Mustard Compounds; 0 / Purines; 8N3DW7272P / Cyclophosphamide; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 12
  •  go-up   go-down


17. Flores G, Committee On Pediatric Research: Technical report--racial and ethnic disparities in the health and health care of children. Pediatrics; 2010 Apr;125(4):e979-e1020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disparities were noted across the spectrum of health and health care, including in mortality rates, access to care and use of services, prevention and population health, health status, adolescent health, chronic diseases, special health care needs, quality of care, and organ transplantation.
  • Mortality-rate disparities were noted for children in all 4 major US racial/ethnic minority groups, including substantially greater risks than white children of all-cause mortality; death from drowning, from acute lymphoblastic leukemia, and after congenital heart defect surgery; and an earlier median age at death for those with Down syndrome and congenital heart defects.

  • MedlinePlus Health Information. consumer health - Health Disparities.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20351000.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  • [Investigator] Denne SC; Bauer AJ; Cabana MD; Cheng TL; Flores G; Notterman DA
  •  go-up   go-down


18. Bidar M, Wilson MW, Laquis SJ, Wilson TD, Fleming JC, Wesley RE, Ribeiro RC, Haik BG: Clinical and imaging characteristics of orbital leukemic tumors. Ophthal Plast Reconstr Surg; 2007 Mar-Apr;23(2):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review was performed on the clinical and imaging records of 27 consecutive patients with a diagnosis of orbital leukemic tumors.
  • The following data were extracted from the patients' records: age at diagnosis of orbital leukemic tumors, sex, race, national origin, type of leukemia, temporal relationship of orbital disease to diagnosis of leukemia, survival from diagnosis of orbital leukemic tumor, laterality of the orbital disease, location of the mass within the orbit, imaging features of the mass, chemotherapeutic protocol, treatment with bone marrow transplant, and orbital radiation.
  • RESULTS: The median age at diagnosis of orbital leukemic tumor was 8 years (range, 1-18 years).
  • Twenty-one patients had acute myeloid leukemia, five had acute lymphoblastic leukemia, and one had chronic myelogenous leukemia.
  • In 85% of patients (n = 23), the diagnosis of leukemia was based on the bone marrow examination findings.
  • Five patients received external beam radiation for the treatment of orbital disease.
  • The median survival for all patients was 4.75 years (range, 0.1-24 years) after the diagnosis of orbital disease.
  • CONCLUSIONS: Orbital leukemic tumors occur most commonly in the first decade of life, in association with acute myeloid leukemia.
  • Although the overall survival rate for patients with leukemia has improved over the past 3 decades, the mortality of patients who develop orbital leukemic tumors remains high.
  • [MeSH-major] Leukemia, Lymphoid / pathology. Leukemia, Myeloid / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Age Distribution. Child. Child, Preschool. Combined Modality Therapy. Diagnostic Imaging. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413619.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 57629; United States / NCI NIH HHS / CA / CA20180; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M: Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia; 2006 Feb;20(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
  • Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear.
  • In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / genetics


20. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


21. Kojima M, Sato E, Oshimi K, Murase T, Koike T, Tsunoda S, Matsumoto T, Marutsuka K, Ogiya D, Moriuchi M, Tokunaka M, Yara Kikuti Y, Kikuchi T, Nakamura N, Ando K: Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases. J Clin Exp Hematop; 2010;50(2):107-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Splenic marginal zone lymphoma (SP-MZL) is a rare low-grade B-cell neoplasm that often shows leukemic manifestation.
  • These results suggest that CD5-positive SP-MZL differs from B-cell chronic lymphocytic leukemia, that CD13 expression is found in about half of CD5-positive SP-MZL cases, and that CD5-positive SP-MZL may be related to memory B-cell neoplasm or plasma cell differentiation.
  • [MeSH-major] Antigens, CD5 / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. Splenic Neoplasms / metabolism. Splenic Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123968.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Kreitman RJ, Pastan I: Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets; 2006 Oct;7(10):1301-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunotoxins, composed of protein toxins connected to cell binding ligands including monoclonal antibodies and growth factors, have been developed for several decades to target hematologic malignancies.
  • Plant toxins, particularly ricin, are useful for chemically conjugating to monoclonal antibodies, and have shown clinical activity in several types of lymphoma and leukemia.
  • Denileukin diftitox has shown efficacy in cutaneous T-cell lymphoma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.
  • Recombinant immunotoxin BL22 is an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin; it induces complete remissions in a high percentage of patients with chemoresistant hairy cell leukemia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17073592.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunotoxins
  • [Number-of-references] 235
  •  go-up   go-down


23. Camacho E, Beà S, Salaverría I, López-Guillermo A, Puig X, Benavente Y, de Sanjosé S, Campo E, Hernández L: Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer; 2006 Jan 15;118(2):357-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma.
  • Aurora-A and hMPS1 are kinases involved in spindle checkpoint and centrosome duplication regulation and whose alterations have been associated with cell transformation and chromosome instability in different tumor models.
  • In this study, we have examined the possible alterations of these genes in 58 mantle cell lymphomas (MCLs) and 4 MCL-related cell lines.
  • Aurora-A was also examined in 46 diffuse large B-cell lymphomas (DLBCLs).
  • No Aurora-A gene amplifications were detected in any tumor or cell line, whereas hemizygous hMPS1 gene deletions were observed in 23% of MCLs and 3 of the 4 cell lines.
  • The Aurora-A proposed cancer susceptibility polymorphic variant (P31I) was observed with a similar frequency in MCL, DLBCL, chronic lymphocytic leukemia and in the 431 healthy controls.
  • [MeSH-major] Cell Cycle Proteins / genetics. Genetic Predisposition to Disease. Lymphoma, Mantle-Cell / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Aurora Kinases. Case-Control Studies. DNA Mutational Analysis. Gene Expression Profiling. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Polymorphism, Genetic. Prognosis. Protein-Tyrosine Kinases. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16080195.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.1 / TTK protein, human
  •  go-up   go-down


24. Jakó J, Szerafin L, Nagy P: [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)]. Orv Hetil; 2005 Mar 6;146(10):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Szekunder carcinomák malignus hematológiai betegségekben (a Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter 1983-2002 közötti adatainak elemzése).
  • INTRODUCTION: The incidence of malignant tumours have increased steadily worldwide.
  • Prior reports indicate that patients with some hematologic malignancies (for example chronic lymphocytic leukemia, non-Hodgkin's lymphoma) may be at increased risk of second neoplasms.
  • PATIENTS, METHODS: Between January 1, 1983 and December 31, 2002, in the county of Szabolcs-Szatmár-Bereg 151 cases with both malignant hematologic diseases and cancers were registered by the authors.
  • In their 60 patients (50 with lymphoid and 10 with myeloid malignancies) the first tumour was the hematologic malignancy.
  • There was a significant connection between lymphoid malignancies and second cancers as compared to myeloid malignancies and subsequent cancers (p < 0.05).
  • The age of patients with second cancers seemed to be not too important, but it was of crucial importance in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
  • The role of immunodeficiency in the development of second cancers may be important in patients with Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia (the number of second cancers in their patients with multiple myeloma and hairy cell leukemia was too small do draw a conclusion).
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Female. Hodgkin Disease / epidemiology. Hodgkin Disease / immunology. Humans. Hungary / epidemiology. Immunocompromised Host. Leukemia / epidemiology. Lymphoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Registries. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835344.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


25. Landman-Parker J, Pagès P, Petit A, Fasola S, Leverger G: [New insights into acute lymphoblastic leukemia]. Bull Acad Natl Med; 2009 Oct;193(7):1501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insights into acute lymphoblastic leukemia].
  • [Transliterated title] Que savons-nous de la cellule leucémique?
  • Acute lymphoblastic leukemia is a malignant disorder of lymphoid progenitor cells.
  • Advances in our understanding of lymphoblastic leukemia have mainly come from new molecular technologies and genomics.
  • This article describes recent advances in our understanding of maturation arrest of leukemic cells, initial and subsequent gene defects and rearrangements, the role of chemokines, and lymphoid cell homing.
  • [MeSH-major] Lymphocyte Subsets / pathology. Neoplastic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Cell Transformation, Neoplastic. Chemokines / physiology. Child. Chromosome Aberrations. Diseases in Twins. Female. Fetal Diseases / genetics. Fetal Diseases / pathology. Fetofetal Transfusion. Humans. Infant. Infant, Newborn. Male. Pregnancy. Receptors, CCR7 / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669631.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / Chemokines; 0 / Receptors, CCR7
  • [Number-of-references] 32
  •  go-up   go-down


26. Slager SL, Kay NE, Fredericksen ZS, Wang AH, Liebow M, Cunningham JM, Vachon CM, Call TG, Cerhan JR: Susceptibility genes and B-chronic lymphocytic leukaemia. Br J Haematol; 2007 Dec;139(5):762-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Susceptibility genes and B-chronic lymphocytic leukaemia.
  • Common genetic variants are thought to increase the risk of chronic lymphocytic leukaemia (CLL), and case-control studies provide an approach to detect these variants.
  • There have been multiple candidate gene studies published to date, but relatively few disease pathway studies or large genomic association studies.
  • However, a number of candidate gene studies have not been replicated in follow-up studies, whereas the results from disease pathway and large genomic studies have yet to be replicated in an independent sample.
  • [MeSH-major] Genetic Predisposition to Disease. Leukemia, Lymphocytic, Chronic, B-Cell / genetics

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021089.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA92153; United States / NCI NIH HHS / CA / U01 CA118444
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


27. Parasole R, Menna G, Marra N, Petruzziello F, Locatelli F, Mangione A, Misuraca A, Buffardi S, Di Cesare-Merlone A, Poggi V: Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leuk Lymphoma; 2008 Aug;49(8):1553-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
  • The treatment of meningeal relapse in acute lymphoblastic leukemia (ALL) remains a challenging clinical problem.
  • [MeSH-major] Cytarabine / administration & dosage. Injections, Spinal. Meningeal Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Aug;49(8):1427-30 [18766957.001]
  • (PMID = 18766969.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


28. Peterson MR, Noskoviak KJ, Newbury R: CD5-positive B-cell acute lymphoblastic leukemia. Pediatr Dev Pathol; 2007 Jan-Feb;10(1):41-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive B-cell acute lymphoblastic leukemia.
  • CD5-positive B-cell acute lymphoblastic leukemia (ALL) is an exceedingly rare entity, with only a single case report in the literature.
  • We report 2 additional cases of CD5-positive B-cell ALL in a 16-year-old male and a 15-year-old female.
  • Cytogenetic analysis of the 2nd case revealed trisomy 22, the 1st time this finding has been reported in ALL.
  • We conclude that CD5-positive B-cell ALL is a rare, aggressive malignancy with a poor prognosis that presents in adolescence.
  • Pathologists and clinicians should be aware of this entity to avoid confusion with other small blue-cell tumors.
  • [MeSH-minor] Adolescent. Antigens, CD / metabolism. Biopsy. Bone Marrow / pathology. Bone Marrow / surgery. Diagnosis, Differential. Diagnostic Errors. Female. Flow Cytometry. Humans. Immunohistochemistry. Leukemia / pathology. Lymphoma / pathology. Male. Prognosis. Sarcoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378623.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Sadawaite S, Jijina F, Nair CK, Seth S, Ghosh K: An unusual presentation of pediatric acute lymphoblastic leukemia. Indian J Hematol Blood Transfus; 2008 Jun;24(2):59-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of pediatric acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is one of the most common hematological malignancies occurring in children.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 1977 Jul;52(7):530-3 [267448.001]
  • [Cites] Med Pediatr Oncol. 1979;6(1):51-5 [286156.001]
  • [Cites] J Pediatr. 1990 Aug;117(2 Pt 1):233-7 [2380822.001]
  • [Cites] N Engl J Med. 2000 Oct 19;343(16):1168-76 [11036124.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):121-33 [9592839.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):589-92 [3276382.001]
  • [Cites] Pediatr Radiol. 1985;15(4):245-8 [3858787.001]
  • [Cites] J Pediatr Orthop. 1994 Jan-Feb;14(1):105-11 [8113359.001]
  • [Cites] Orthop Clin North Am. 1996 Jul;27(3):635-44 [8649744.001]
  • (PMID = 23100945.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453041
  • [Keywords] NOTNLM ; ALL / Fracture / Osteoporosis
  •  go-up   go-down


30. Ford AM, Martínez-Ramírez A: Therapeutic opportunities and targets in childhood leukemia. Clin Transl Oncol; 2006 Aug;8(8):560-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic opportunities and targets in childhood leukemia.
  • Childhood leukemia is a common pediatric cancer in the developed world, the disease is biologically diverse and there is much discussion as to its causal mechanisms.
  • Acute lymphoblastic leukemia (ALL) is the most common subtype and infants with ALL have a greatly increased risk of treatment failure.
  • Therapeutic concepts using monoclonal antibodies have substantially improved response rates in patients with malignant lymphomas and are currently being evaluated in other types of cancer.
  • [MeSH-major] Leukemia / genetics. Leukemia / therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / therapeutic use. Child. Child, Preschool. Humans. Immunization, Passive. Immunotherapy, Active. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cells

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):268-73 [14582077.001]
  • [Cites] Oncogene. 2002 Dec 9;21(56):8652-67 [12476311.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5828-39 [10913166.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Sep;17(3):251-8 [9894758.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 2001 Aug 1;98(3):558-64 [11468150.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Br J Haematol. 1969 Dec;17(6):603-4 [4391089.001]
  • [Cites] Early Hum Dev. 2005 Jan;81(1):123-9 [15707724.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2887-93 [11698267.001]
  • [Cites] Blood. 2000 Jul 1;96(1):24-33 [10891426.001]
  • [Cites] Mol Pharmacol. 2005 Oct;68(4):917-32 [15955865.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):201-5 [14648023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4263-9 [7492786.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Arch Med Res. 2003 Nov-Dec;34(6):507-14 [14734090.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2557-61 [11001911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4917-21 [7761424.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4584-8 [9539781.001]
  • [Cites] J Biol Regul Homeost Agents. 2005 Jan-Jun;19(1-2):23-32 [16178271.001]
  • [Cites] Leukemia. 2001 Jun;15(6):987-9 [11417488.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):345-52 [12042710.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):616-21 [10886212.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4252-8 [8943861.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S30-5 [16341238.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] JAMA. 2005 Sep 21;294(11):1359-66 [16174694.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2124-31 [15528316.001]
  • (PMID = 16952844.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 41
  •  go-up   go-down


31. Butler RW, Mulhern RK: Neurocognitive interventions for children and adolescents surviving cancer. J Pediatr Psychol; 2005 Jan-Feb;30(1):65-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It is well recognized that many cures for childhood leukemia and brain tumors entail some relatively permanent neurocognitive and psychological costs to the patient and family.
  • OBJECTIVE: The particular focus of this review will be on interventions for the neuropsychological late effects associated with the treatment of acute lymphoblastic leukemia (ALL) and malignant brain tumors.
  • [MeSH-major] Brain Neoplasms / drug therapy. Cognition Disorders / etiology. Cognition Disorders / therapy. Cognitive Therapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Disease-Free Survival. Drug-Related Side Effects and Adverse Reactions. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Psychol. 2005 Jan-Feb;30(1):79-84 [15610987.001]
  • [CommentIn] J Pediatr Psychol. 2005 Jan-Feb;30(1):85-8 [15610988.001]
  • (PMID = 15610986.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA83936-01
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


32. Chiotoglou I, Smilevska T, Samara M, Likousi S, Belessi C, Athanasiadou I, Stavroyianni N, Samara S, Laoutaris N, Vamvakopoulos N, Anagnostopoulos A, Fassas A, Stamatopoulos K, Kollia P: Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors. Blood Cells Mol Dis; 2008 Sep-Oct;41(2):203-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors.
  • Several lines of evidence suggest that chronic lymphocytic leukemia (CLL) malignant B cells resemble antigen-experienced and activated B cells.
  • In the present study, we investigated the expression of transferrin receptor 1 (TfR1, CD71), one of the "classical" markers up-regulated upon B-cell activation, and TfR2, a novel receptor for transferrin, in peripheral blood CD19+ B cells from ten healthy individuals and 76 patients with CLL so as to gain insight into potential disease-related differences in underlying regulatory mechanisms.
  • Marked differences in the production and expression of these receptors were detected in malignant but not in normal B cells.
  • Specifically, TfR1 mRNA and protein levels were significantly higher in comparison to TfR2, both in normal and malignant B cells.
  • Exposure to actinomycin D decreased TfR1 and TfR2 mRNA levels in normal CD19+ B cells but had no effect on CLL malignant cells.
  • The protein synthesis inhibitor cycloheximide had opposing effects in normal vs. CLL malignant B cells: thus, TfR1 and TfR2 mRNA levels were increased in normal B cells, whereas they were unaffected or even suppressed in CLL malignant B cells.
  • This type of control appears to be especially suited for modulation of genes implicated in proliferation of activated cells, like CLL malignant B cells.
  • [MeSH-major] B-Lymphocytes / chemistry. Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Receptors, Transferrin / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621559.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD71 antigen; 0 / RNA, Messenger; 0 / Receptors, Transferrin; 0 / TFR2 protein, human; 1CC1JFE158 / Dactinomycin; 98600C0908 / Cycloheximide
  •  go-up   go-down


33. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D: Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood; 2010 Sep 9;116(10):1795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
  • Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT) from related (n = 13) or unrelated (n = 27) donors for the treatment of advanced non-Hodgkin lymphoma.
  • Diagnoses were follicular lymphoma (n = 17), chronic lymphocytic leukemia (n = 13), mantle cell lymphoma (n = 8), marginal zone lymphoma (n = 1), and lymphoplasmacytic lymphoma (n = 1).
  • All patients were high risk with refractory disease or relapse after preceding autologous HCT.
  • Incidences of acute graft-versus-host disease 2-4 and chronic graft-versus-host disease were 43% and 53%, respectively.
  • Twenty-two of 40 patients (55%) are alive, resulting in a Kaplan-Meier-estimated 2-year survival of 51% for all, 67% for follicular lymphoma, 49% for chronic lymphocytic leukemia, and 37% for mantle cell lymphoma patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / surgery. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / chemistry. Combined Modality Therapy. Female. Graft vs Host Disease / etiology. Hematologic Diseases / etiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Yttrium Radioisotopes / chemistry. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530284.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00302757
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


34. Martinez A, Pittaluga S, Rudelius M, Davies-Hill T, Sebasigari D, Fountaine TJ, Hewitt S, Jaffe ES, Raffeld M: Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker. Am J Surg Pathol; 2008 Aug;32(8):1190-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.
  • To assess the role of interferon regulatory factor (IRF) 8 in B-cell development and lymphomagenesis, we studied its expression in reactive lymphoid tissues, its relationship to other B-cell transcription factors, and its expression in a series of 232 B-cell tumors and 30 cell lines representing a variety of B-cell developmental stages.
  • IRF8 was coexpressed with PAX-5, Pu.1, and B-cell lymphoma (BCL)-6, and similar to BCL-6, was absent from the small population of IRF4-positive germinal center B cells thought to be committed to postgerminal center developmental programs.
  • Similarly, IRF8 was most strongly expressed in lymphomas of germinal center origin with lower levels present in mantle cell lymphomas, chronic lymphocytic leukemia, and marginal zone lymphomas, and no expression observed in plasmacytic/plasmablastic neoplasms.
  • These results suggest an important role for IRF8 during germinal center B-cell development and in related lymphomas, and provide a new diagnostic marker helpful in distinguishing B-cell non-Hodgkin lymphoma subtypes.
  • [MeSH-major] B-Lymphocytes / metabolism. Biomarkers, Tumor / metabolism. Germinal Center / metabolism. Interferon Regulatory Factors / metabolism. Lymphoma, B-Cell / metabolism
  • [MeSH-minor] B-Cell-Specific Activator Protein / metabolism. Cell Line, Tumor. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, Mantle-Cell / metabolism. Palatine Tonsil / chemistry. Plasma Cells / metabolism. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580679.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / PAX5 protein, human; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / interferon regulatory factor-4; 0 / interferon regulatory factor-8; 0 / proto-oncogene protein Spi-1
  •  go-up   go-down


35. Wiemels JL, Hofmann J, Kang M, Selzer R, Green R, Zhou M, Zhong S, Zhang L, Smith MT, Marsit C, Loh M, Buffler P, Yeh RF: Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally. Cancer Res; 2008 Dec 1;68(23):9935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally.
  • TEL-AML1 (ETV6-RUNX1) is the most common translocation in the childhood leukemias, and is a prenatal mutation in most children.
  • This translocation has been detected at a high rate among newborns ( approximately 1%); therefore, the rate-limiting event for leukemia seems to be secondary mutations.
  • One such frequent mutation in this subtype is partial deletion of chromosome 12p, trans from the translocation.
  • Nine del(12p) breakpoints within six leukemia cases were sequenced to explore the etiology of this genetic event, and most involved cryptic sterile translocations.
  • An exploratory assessment of archived neonatal blood cards revealed significantly more long interspersed nuclear element CpG methylations in individuals at birth who were later diagnosed with TEL-AML1 leukemia, compared with individuals who did not contract leukemia (P=0.01).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4640-1 [12756163.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):138-49 [14685282.001]
  • [Cites] Nature. 2004 Mar 4;428(6978):88-93 [14999286.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4275-83 [15156184.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8443-8 [15155899.001]
  • [Cites] Mol Cells. 2004 Apr 30;17(2):217-22 [15179033.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1499-504 [15284860.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 17;322(2):623-30 [15325275.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5355-60 [15328172.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5533-56 [2838820.001]
  • [Cites] Biochemistry. 1993 Nov 30;32(47):12782-92 [7504526.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2891-9 [8639909.001]
  • [Cites] Mol Cell Biol. 1997 Jun;17(6):3125-36 [9154811.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4584-8 [9539781.001]
  • [Cites] Blood. 1999 Jan 1;93(1):293-9 [9864173.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4075-82 [10463610.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):305-19 [16075461.001]
  • [Cites] Oncogene. 2005 Nov 3;24(48):7213-23 [16170379.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7720-7 [16278392.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15166-71 [17015828.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4404-14 [17237815.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Nucleic Acids Res. 2008 Feb;36(3):770-84 [18084025.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] J Mol Biol. 2006 Apr 14;357(5):1383-93 [16490214.001]
  • [Cites] BMC Cancer. 2006;6:100 [16630339.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Gene. 1999 Nov 29;240(2):297-305 [10580149.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Nov;29(3):219-28 [10992297.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Leukemia. 2001 May;15(5):858-9 [11368451.001]
  • [Cites] Blood. 2001 Jul 15;98(2):478-82 [11435320.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Blood. 2001 Aug 1;98(3):558-64 [11468150.001]
  • [Cites] Nucleic Acids Res. 2001 Nov 1;29(21):4493-501 [11691937.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):372-4 [11752340.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2068-77 [11884595.001]
  • [Cites] Eur J Hum Genet. 2002 Jan;10(1):62-71 [11896457.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):155-64 [12526921.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):156-60 [14695996.001]
  • (PMID = 19047175.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P42-ES04705; United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / R01 CA089032-04A1; United States / NCI NIH HHS / CA / R01 CA089032-06; United States / NCI NIH HHS / CA / CA89032; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NIEHS NIH HHS / ES / R01 ES09137; United States / NCI NIH HHS / CA / CA089032-04A1; United States / NCI NIH HHS / CA / R01 CA089032-05; United States / NIEHS NIH HHS / ES / R01 ES009137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Retroelements; 0 / TEL-AML1 fusion protein
  • [Other-IDs] NLM/ NIHMS74688; NLM/ PMC2597307
  •  go-up   go-down


36. Bussotti EA, Ribeiro Leão E, Nascimento Chimentão DM, Rodrigues Silva CP: [Individulized care: can I bring my dog?]. Rev Esc Enferm USP; 2005 Jun;39(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case study aimed at knowing the perception of a teenager suffering from recurrent acute lymphocytic leukemia and of her mother regarding the visit of her pet dog during hospitalization, as well as at describing the experience as a nursing intervention.
  • [MeSH-major] Bonding, Human-Pet. Dogs. Infection Control / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Visitors to Patients

  • MedlinePlus Health Information. consumer health - Infection Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16060307.001).
  • [ISSN] 0080-6234
  • [Journal-full-title] Revista da Escola de Enfermagem da U S P
  • [ISO-abbreviation] Rev Esc Enferm USP
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


37. Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, Lafon I, Cornillon J, Maakaroun A, Tizon A, Padrazzi B, Ifrah N, Gruel Y, GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang): Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica; 2008 Oct;93(10):1488-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
  • DESIGN AND METHODS: This was a retrospective analysis of 214 patients treated with L-asparaginase (7500 IU/m(2) x 6) for acute lymphoblastic leukemia or lymphoblastic lymphoma.
  • In patients who received antithrombin concentrates L-asparaginase injections were less frequently omitted or delayed (53% vs. 72%, p=0.005), the rate of thrombosis was lower (4.8% vs. 12.2%, p=0.04) and the disease-free survival was also reduced (p=0.05).
  • CONCLUSIONS: This retrospective study suggests that antithrombin concentrates may have a beneficial effect on the outcome of adults treated for acute lymphoblastic leukemia with L-asparaginase; prospective studies are essential to confirm this hypothesis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antithrombins / metabolism. Asparaginase / pharmacology. Fibrinogen / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Hemorrhage / metabolism. Hemorrhage / pathology. Humans. Male. Middle Aged. Survival Rate. Thrombosis / metabolism. Thrombosis / prevention & control. Treatment Outcome


38. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA, EUROCARE Working Group: Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer; 2009 Apr;45(6):992-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival improved significantly over time for acute lymphoid leukaemia and primitive neuroectodermal tumours in children and for non-Hodgkin lymphoma in adolescents/young adults.
  • Complete cancer registration should be a priority for these countries as an essential part of a policy for effective cancer control in Europe.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Epidemiologic Methods. Europe / epidemiology. Female. Humans. Infant. Male. Rare Diseases / mortality. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231160.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Oberaigner W; Hackl M; Van Eycken E; Verstreken M; Holub J; Jurickova L; Storm HH; Engholm G; Hakulinen T; Belot A; Hédelin G; Velten M; Tron I; Le Gall E; Launoy G; Guizard AV; Faivre J; Bouvier AM; Carli PM; Maynadié M; Danzon A; Buemi A; Tretarre B; Lacour B; Desandes E; Colonna M; Molinié F; Bara S; Schvartz S; Ganry O; Grosclaude P; Brenner H; Kaatsch P; Ziegler H; Tryggvadottir L; Comber H; Berrino F; Allemani C; Baili P; Ciampichini R; Ciccolallo L; Gatta G; Micheli A; Sant M; Sowe S; Zigon G; Tagliabue G; Contiero P; Bellù F; Giacomin A; Ferretti S; Dal Maso DS; De Dottori M; De Paoli A; Zanier L; Vercelli M; Orengo MA; Casella C; Quaglia A; Pannelli F; Federico M; Rashid I; Cirilli C; Fusco M; Traina A; De Lisi V; Bozzani F; Magnani C; Pastore G; Tumino R; La Rosa MG; Spata E; Sigona A; Mangone L; Falcini F; Foca F; Giorgetti S; Senatore G; Iannelli A; Budroni M; Zanetti R; Patriarca S; Rosso S; Piffer S; Franchini S; Paci E; Crocetti E; La Rosa F; Stracci F; Cassetti T; Zambon P; Guzzinati S; Caldora M; Capocaccia R; Carrani E; De Angelis R; Francisci S; Grande E; Inghelmann R; Lenz H; Martina L; Roazzi P; Santaquilani M; Simonetti A; Tavilla A; Verdecchia A; Dalmas M; Langmark F; Bray F; Johannesen TB; Rachtan J; Góźdź S; Siudowska U; Mezyk R; Bielska-Lasota M; Zwierko M; Pinheiro PS; Primic-Zakelj M; Mateos A; Izarzugaza I; Torrella-Ramos A; Zurriaga O; Marcos-Gragera R; Vilardell ML; Izquierdo A; Martinez-Garcia C; Sánchez MJ; Navarro C; Chirlaque MD; Peris-Bonet R; Ardanaz E; Moreno C; Galceran J; Klint A; Talbäck M; Jundt G; Usel M; Frick H; Ess SM; Bordoni A; Luthi JC; Konzelmann I; Probst N; Lutz JM; Pury P; Visser O; Otter R; Schaapveld M; Coebergh JW; Janssen-Heijnen ML; van der Heijden L; Greenberg DC; Coleman MP; Woods L; Moran T; Forman D; Cooper N; Roche M; Verne J; Møller H; Meechan D; Poole J; Lawrence G; Stiller C; Gavin A; Black RJ; Brewster DH; Steward JA
  •  go-up   go-down


39. Hassan R, Felisbino F, Stefanoff CG, Pires V, Klumb CE, Dobbin J, Seuánez HN, Renault IZ: Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects. Eur J Haematol; 2008 Mar;80(3):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects.
  • Burkitt lymphoma/leukaemia (BL/L) is a heterogeneous disease with respect to epidemiological patterns and cell origin.
  • The occurrence of BL/L with an immature phenotype raises the question whether this phenotype might be a consequence of early B-cell transformation or, alternatively, a secondary feature of transformed, mature B cells.
  • It also poses important clinical questions regarding diagnosis and therapeutic procedures.
  • Here we describe the case of a 4-yr-old child with BL/L and FAB L3 morphology, with phenotypic and genotypic characteristics of a CD10+ precursor B-cell acute lymphoid leukaemia (ALL) associated with t(8;14)(q24;q32).
  • Molecular analysis showed expression of RAG1 and RAG2 and an unmutated VDJCmu immunoglobulin rearrangement coinciding with a lack of AICDA expression, indicating an immature B-cell origin.
  • His clinical response suggested that FAB L3 ALL with MYC rearrangement and an aberrant precursor B-cell phenotype is clinically similar to BL/L.
  • This case also allowed us to refine the description of cellular and molecular variants of BL/L regarding the cell origin and pathogenesis of this biologically heterogeneous disease.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cell Transformation, Neoplastic / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cells, B-Lymphoid / pathology
  • [MeSH-minor] Cell Differentiation / physiology. Child, Preschool. Diagnosis, Differential. Gene Fusion. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, myc. Humans. Immunoglobulin Heavy Chains / genetics. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005389.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


40. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S: Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant; 2005 Nov;36(10):867-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
  • Disease-free survival in Philadelphia chromosome-positive ALL (Ph + ALL) is very poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently considered the only procedure with curative potential.
  • The 5-year survival rates were 34% for patients in first complete remission (CR), 21% for those in second or subsequent CR, and 9% for those with active disease (P < 0.0001).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Female. Graft vs Host Disease / mortality. Humans. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Recurrence. Registries. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Whole-Body Irradiation / statistics & numerical data


41. Wada H, Sakakura M, Fujieda A, Sakaguchi A, Abe Y: [Markedly increased red cell fragmentations counted as platelets in a patient with thrombotic microangiopathy]. Rinsho Byori; 2005 Apr;53(4):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Markedly increased red cell fragmentations counted as platelets in a patient with thrombotic microangiopathy].
  • A patient with acute lymphocytic leukemia (ALL) experienced severe thrombotic microangiopathy (TMA) after allo-bone marrow transplantation (BMT).
  • She had high risk for TMA; due to total body irradiation (TBI), intensive chemotherapy, treatment with Ciclosporin and association with veno-occlusive disease (VOD).
  • Careful evaluation of the platelet count is necessary in patients with red cell fragmentations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915766.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Hosono N, Kishi S, Iho S, Urasaki Y, Yoshida A, Kurooka H, Yokota Y, Ueda T: Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line. Cancer Sci; 2010 Mar;101(3):767-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line.
  • Recently GSTM1 has been reported to be a significant risk factor for hematological relapse in childhood acute lymphoblastic leukemia, although the underlying mechanism remains largely unknown.
  • Glucocorticoids play a crucial role in the treatment of childhood acute lymphoblastic leukemia, therefore we hypothesized that GSTM1 plays important roles in glucocorticoid-induced apoptotic pathways.
  • To clarify the relationship between GSTM1 and drug resistance, GSTM1 was transfected into a T-acute lymphoblastic leukemia cell line, CCRF-CEM (CEM), and we established the GSTM1-expressing cell lines CEM/M1-4 and CEM/M1-9.
  • [MeSH-major] Apoptosis / drug effects. Apoptosis Regulatory Proteins / antagonists & inhibitors. Dexamethasone / pharmacology. Glutathione Transferase / physiology. Membrane Proteins / antagonists & inhibitors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Proto-Oncogene Proteins / antagonists & inhibitors
  • [MeSH-minor] Buthionine Sulfoximine / pharmacology. Cell Line, Tumor. Drug Resistance, Neoplasm. Humans. NF-kappa B p50 Subunit / physiology. p38 Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067466.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Membrane Proteins; 0 / NF-kappa B p50 Subunit; 0 / Proto-Oncogene Proteins; 5072-26-4 / Buthionine Sulfoximine; 7S5I7G3JQL / Dexamethasone; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


43. Naghashpour M, Lancet J, Moscinski L, Zhang L: Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report. Am J Hematol; 2010 Jun;85(6):451-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
  • The majority of cases of acute leukemia belong to a specific lineage origin, either lymphoid or myeloid, and therefore are classified as acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML), based on morphologic features and cytochemical and immunophenotypic profile of the blast cells.
  • A minority of acute leukemias however, show no clear evidence of differentiation along a single lineage.
  • These are now classified under acute leukemias of ambiguous lineage by the most recent WHO classification and account for <4% of all cases of acute leukemia [1].
  • They include leukemias with no lineage specific antigens (acute undifferentiated leukemias) and those with blasts that express antigens of more than one lineage to such degree that it is not possible to assign the leukemia to any one particular lineage with certainty (mixed phenotype acute leukemias).
  • The latter can either be leukemias with two distinct populations of blasts, each expressing antigens of a different lineage (historically referred to as "bilineal" leukemias) or a single blast population expressing antigens of multiple lineages (historically referred to as "biphenotypic" acute leukemias) [2].
  • Acute leukemias of ambiguous lineage may harbor a variety of genetic lesions.
  • Those with t(9;22)(q34;q11) or translocations associated with mixed lineage leukemias (MLL) gene, i.e., t(11;V)(q23;V), occur frequently enough and are associated with distinct features, that are considered as separate entities according to the recent WHO classification.
  • Co-expression of myeloid and B-lymphoid antigens is most common in mixed phenotype acute leukemia (MPAL), followed by co-expression of myeloid and T-lymphoid antigens, accounting for 66-70% and 23-24% of MLLs, respectively.
  • The requirements for assigning more than one lineage to a single blast population has been established by current WHO classification [1].
  • [MeSH-major] Antigens, Neoplasm / blood. Chromosomes, Human, Pair 11 / ultrastructure. Chromosomes, Human, Pair 19 / ultrastructure. Immunophenotyping. Leukemia / classification. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD / analysis. Bone Marrow / pathology. Cell Lineage. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20513125.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / MLL-ENL oncoprotein, human; 0 / MLLT1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


44. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T: High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther; 2006 Nov;80(5):468-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
  • Subsequently, we assessed the association of polymorphisms with the methotrexate plasma concentrations in 44 pediatric patients with acute lymphoblastic leukemia (ALL) (29 male and 15 female patients; mean age, 6.8+/-4.8 years).
  • [MeSH-major] Membrane Transport Proteins / genetics. Methotrexate / pharmacokinetics. Methotrexate / therapeutic use. Multidrug Resistance-Associated Proteins / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


45. Alikasifoglu A, Yetgin S, Cetin M, Tuncer M, Gumruk F, Gurgey A, Yordam N: Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. Am J Hematol; 2005 Oct;80(2):113-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments.
  • During recent decades, the survival rate after childhood acute lymphoblastic leukemia (ALL) has improved substantially; consequently, the long-term side effects of ALL and its treatment have gained attention, of which osteoporosis is one of the most important.
  • Stepwise regression analysis revealed that lumbar spine BMD z scores was predicted by height SDS and the time past since cessation of therapy, but not age at diagnosis, BMI SDS, cranial radiotherapy, and puberty.
  • [MeSH-major] Bone Density / drug effects. Bone Remodeling / drug effects. Methylprednisolone / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / adverse effects


46. Uzunhan Y, Cadranel J, Boissel N, Gardin C, Arnulf B, Bergeron A: [Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas)]. Rev Mal Respir; 2010 Jun;27(6):599-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas)].
  • INTRODUCTION - BACKGROUND: The non infectious pulmonary manifestations occurring in lymphoplasmocytic proliferations others than lymphomas are poorly understood and have rarely been the object of dedicated publications.
  • VIEWPOINTS: The purpose of this work is to review the literature of the various specific lung manifestations occurring during these malignant haematological diseases.
  • We will also consider acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and hairy cell leukaemia, as well as malignant plasmocytic disorders such as myeloma, POEMS syndrome and Waldenström's macroglobulinaemia.
  • CONCLUSION: During the course of lymphoplasmocytic diseases, lung manifestations are variable and sometimes require invasive techniques for definitive diagnosis.
  • [MeSH-major] Lung Diseases / etiology. Lymphoproliferative Disorders / complications
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Multiple Myeloma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Waldenstrom Macroglobulinemia / complications

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20610075.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


47. Janel A, Bonnemoy S, Mathevon T, Sapin V: [Pseudo-hyperkalaemia and chronical lymphoïd leukaemia: about one observation]. Ann Biol Clin (Paris); 2009 May-Jun;67(3):338-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-hyperkalaemia and chronical lymphoïd leukaemia: about one observation].
  • This gap is explained by the high leukocytosis of this patient (561 G/L) within a context of chronic lymphocytic leukemia as well as by the fragility of these cells revealed by specific rules for samples transport between the clinical departments and the central laboratory.
  • [MeSH-major] Heart Failure / etiology. Hyperkalemia / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411237.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] RWP5GA015D / Potassium
  •  go-up   go-down


48. Schulenburg A, Brämswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, Pehamberger H, Grunt T, Jäger U, Zielinski CC, Valent P: Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol; 2010 Nov;76(2):79-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplastic stem cells have initially been characterized in myeloid leukemias where NOD/SCID mouse-repopulating progenitors supposedly reside within a CD34+/Lin- subset of the malignant clone.
  • In some lymphoid leukemias, NOD/SCID mouse-repopulating cells were also reported to reside within the CD34+/Lin- subfraction of the clone.
  • More recently, several attempts have been made to transfer the cancer stem cell concept to solid tumors and other non-hematopoietic neoplasms.
  • In several of these tumors, the cell surface antigens AC133 (CD133) and CD44 are considered to indicate the potential of a cell to initiate permanent tumor formation in vivo.
  • However, several questions concerning the phenotype, self-renewal capacity, stroma-dependence, and other properties of cancer- or leukemia-initiating cells remain to be solved.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20185329.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


49. Ivanovski P, Alqam M, Ivanovski I: Case-control studies compare "apples and pears": Proposal for a retrospective cohort study in the USA of vaccination history in relation to subsequent childhood leukemia. Med Hypotheses; 2008 Dec;71(6):892-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control studies compare "apples and pears": Proposal for a retrospective cohort study in the USA of vaccination history in relation to subsequent childhood leukemia.
  • The role of vaccination in triggering childhood acute lymphoblastic leukemia (ALL) has been assessed in many studies.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Hypotheses. 2009 May;72(5):614-5 [19157717.001]
  • (PMID = 18774234.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


50. Andreeva SV, Drozdova VD, Emel'ianenko LA: [Chromosome 11 rearrangements in the different haematological neoplasias]. Tsitol Genet; 2007 Mar-Apr;41(2):42-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases of chromosome 11 abnormalities in leukemic bone marrow cells have constituted 14.0% in acute lymphoblastic leukemia (ALL), 18.7% in acute myeloid leukemia (AML), and 16.7% in refractory anemia (RA).
  • The results have showed the poor prognosis of the abnormalities not only of 11q21, 11q23 in acute leukemia (AL), but of 11p13, 11p15 in AML as well, while not enough data on this subject is availalbe in the literature.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid / genetics. Myelodysplastic Syndromes / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Bone Marrow Cells / pathology. Child. Child, Preschool. Chromosome Banding. Female. Humans. Infant. Karyotyping. Male

  • Genetic Alliance. consumer health - Chromosome 11.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17494343.001).
  • [ISSN] 0564-3783
  • [Journal-full-title] T︠S︡itologii︠a︡ i genetika
  • [ISO-abbreviation] Tsitol. Genet.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


51. Biondi A, Rizzari C, Valsecchi MG, De Lorenzo P, Aricò M, Basso G, Locatelli F, Lo Nigro L, De Rossi G, Masera G: Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica; 2006 Apr;91(4):534-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
  • Fifty-two infants with acute lymphoblastic leukemia (ALL) enrolled in the AIEOP ALL-91 and ALL-95 studies were treated with the intermediate or high risk protocols according to their presenting features and early response to treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Methotrexate / therapeutic use. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537119.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


52. Demacq C, Vasconcellos VB, Izidoro-Toledo TC, da Silva Silveira V, Canalle R, Queiroz RG, Tone LG, Tanus-Santos JE: Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL). Clin Chim Acta; 2010 Sep 6;411(17-18):1335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL).
  • We examined the association among functional polymorphisms in these two angiogenesis related genes: VEGF (-2578C>A, -1154G>A, and -634G>C) and NOS3 (-786T>C, intron 4 b>a, and Glu298Asp) with prognosis of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Nitric Oxide Synthase Type III / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Base Sequence. Child. Child, Preschool. DNA Primers. Disease-Free Survival. Female. Genotype. Haplotypes. Humans. Male. Recurrence. Risk Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20510681.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


53. Aytaç S, Yetgin S, Tavil B: Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. Turk J Pediatr; 2006 Jan-Mar;48(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute and long-term neurologic complications in children with acute lymphoblastic leukemia.
  • We reviewed the pattern of acute and long-term (during and after treatment period) neurologic complications in children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Nervous System Diseases / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16562778.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 5J49Q6B70F / Vincristine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


54. Nyári TA, Kajtár P, Bartyik K, Thurzó L, Parker L: Childhood acute lymphoblastic leukaemia in relation to population mixing around the time of birth in South Hungary. Pediatr Blood Cancer; 2006 Dec;47(7):944-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukaemia in relation to population mixing around the time of birth in South Hungary.
  • In a retrospective epidemiological study of 481,984 live births in South Hungary, we investigated whether higher levels of population mixing around the time of birth is a risk factor for acute lymphoblastic leukemia (ALL) under age 5 years.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Dec;47(7):974; author reply 975 [16646027.001]
  • (PMID = 16421899.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Kalmanti M, Stiakaki E, Mantadakis E, Martimianaki G, Giannoulia A, Kalmonti L, Dimitriou H: Assessment of megakaryopoiesis in children with acute lymphoblastic leukemia. Acta Haematol; 2005;114(2):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of megakaryopoiesis in children with acute lymphoblastic leukemia.
  • The effect of the underlying disease and chemotherapy on megakaryopoiesis has not been extensively studied in children with acute lymphoblastic leukemia (ALL) during and at the end of therapy.
  • A significant reduction in the number of Mk colonies was observed at diagnosis of ALL, and Mk colony formation remained lower than controls throughout the different phases of leukemia treatment.
  • [MeSH-major] Megakaryocytes. Myeloid Progenitor Cells. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Thrombopoiesis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16103631.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


56. Chang H, Cerny J: Molecular characterization of chronic lymphocytic leukemia with two distinct cell populations: Evidence for separate clonal origins. Am J Clin Pathol; 2006 Jul;126(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of chronic lymphocytic leukemia with two distinct cell populations: Evidence for separate clonal origins.
  • We report a case of an elderly woman with persistent lymphocytosis in whom flow cytometric immunophenotyping revealed 2 distinct clonal B-cell populations with different light chain restrictions.
  • Fluorescence in situ hybridization (FISH) analysis revealed trisomy 12 in the lambda-restricted B-cell clone, whereas the k-restricted population had normal FISH patterns.
  • Our results demonstrated that the immunophenotypically different cell populations originated from 2 separate clones.
  • [MeSH-major] Cell Lineage / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Aged, 80 and over. Antigens, CD / metabolism. Antineoplastic Agents, Alkylating / therapeutic use. Cell Differentiation. Chlorambucil / therapeutic use. Clone Cells / immunology. Clone Cells / pathology. Female. Flow Cytometry. Gene Rearrangement / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753602.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin Heavy Chains; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


57. Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, Thithapandha A, Hongeng S: Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Jan;48(1):16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia.
  • This study was performed to evaluate the effect of the polymorphisms of DNA repair genes on risk of childhood acute lymphoblastic leukemia (ALL).
  • In contrast, individuals with the XRCC1 399Gln allele and haplotype C were associated with increased risk for this disease.
  • [MeSH-major] Alleles. DNA Repair. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16435384.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1
  •  go-up   go-down


58. Heinsohn S, Golta S, Kabisch H, zur Stadt U: Standardized detection of Simian virus 40 by real-time quantitative polymerase chain reaction in pediatric malignancies. Haematologica; 2005 Jan;90(1):94-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used 500 ng of the COS-1 cell line, containing one single integrated copy of SV40 DNA, as the quantification standard.
  • DNA samples from 149 healthy controls, from 26 fresh frozen childhood cases of acute lymphoblastic leukemia (ALL) (B-, BCP- and T-ALL) and from 12 paraffin-embedded osteosarcomas were investigated.
  • [MeSH-major] Osteosarcoma / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Simian virus 40 / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Jan;90(1):6 [15644307.001]
  • (PMID = 15642675.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


59. Liu HC, Hung GY, Yen HJ, Hsieh MY, Chiou TJ: Acute sciatica: an unusual presentation of extramedullary relapse of acute lymphoblastic leukemia. Int J Hematol; 2007 Aug;86(2):163-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute sciatica: an unusual presentation of extramedullary relapse of acute lymphoblastic leukemia.
  • A 10-year-old boy who had been treated for acute lymphoblastic leukemia presented with persistent numbness of the left big toe and progressive pain of the ipsilateral lower leg.
  • Unfortunately, he didn't survive because of a fungal sepsis that developed during the neutropenic state.
  • This case represents a rare neurologic complication of what is currently an uncommon presentation for relapse of acute lymphoblastic leukemia, with acute sciatica and without coexisting epidural or leptomeningeal leukemia.
  • [MeSH-major] Leukemic Infiltration / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Sciatica / etiology
  • [MeSH-minor] Acute Disease. Child. Humans. Leg / pathology. Magnetic Resonance Imaging. Male. Muscle, Skeletal / injuries. Muscle, Skeletal / pathology. Recurrence. Sciatic Nerve / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Sciatica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Formos Med Assoc. 1998 Apr;97(4):252-60 [9585676.001]
  • [Cites] Arch Neurol. 1994 Jun;51(6):618-22 [8198473.001]
  • [Cites] J Trauma. 1999 Nov;47(5):986-91 [10568739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):439-44 [2394621.001]
  • [Cites] Haematologica. 2006 May;91(5 Suppl):ECR07 [16709515.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):147-52 [10918424.001]
  • [Cites] Neurology. 1987 Mar;37(3):474-7 [3469539.001]
  • [Cites] Ann Hematol. 2003 Feb;82(2):124-6 [12601494.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2047-50 [3167817.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):235-7 [11889376.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1990 Aug;19(3):259-64 [2210952.001]
  • [Cites] Ann Intern Med. 1991 Jul 1;115(1):13-8 [2048858.001]
  • (PMID = 17875532.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2006;:133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult acute lymphoblastic leukemia.
  • In the early 1980s, adult acute lymphoblastic leukemia (ALL) was a rarely curable disease with overall survival < 10%.
  • Improvements to standard therapy including stem cell transplantation (SCT) have occurred and a variety of new drugs for ALL are under evaluation.
  • Rapid diagnosis and classification of ALL is increasingly important to identify prognostic factors and molecular genetic subsets that will be the focus of "targeted" therapies as we enter the era of subset specific treatment.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124052.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


61. Kaufman M, Rubin J, Rai K: Diagnosing and treating chronic lymphocytic leukemia in 2009. Oncology (Williston Park); 2009 Nov 15;23(12):1030-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing and treating chronic lymphocytic leukemia in 2009.
  • Over the past decade, major breakthroughs have been made in both the molecular understanding and the treatment of chronic lymphocytic leukemia (CLL).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Nov 15;23(12):1046, 1051, 1056 [20017287.001]
  • [CommentIn] Oncology (Williston Park). 2009 Nov 15;23(12):1043, 1046 [20017286.001]
  • (PMID = 20017285.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor
  • [Number-of-references] 40
  •  go-up   go-down


62. Shahgholi E, Ehsani MA, Salamati P, Maysamie A, Sotoudeh K, Mokhtariazad T: Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer; 2010 May;54(5):716-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy.
  • PURPOSE: The aim of this study was to assess the immune response of children with acute lymphoblastic leukemia (ALL) to influenza vaccine and to compare it with healthy controls.
  • [MeSH-major] Immunocompromised Host. Influenza Vaccines / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Influenza A Virus, H1N1 Subtype. Influenza A Virus, H3N2 Subtype. Influenza B virus. Influenza, Human / prevention & control. Influenza, Human / virology. Iran. Male. Vaccines, Combined

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205258.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Influenza Vaccines; 0 / Vaccines, Combined
  •  go-up   go-down


63. Beyan C, Kaptan K, Ifran A: Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis. Ann Hematol; 2006 Nov;85(11):811-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis.
  • [MeSH-major] Hashimoto Disease / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845514.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


64. Parreño M, Vaqué JP, Casanova I, Frade P, Céspedes MV, Pavón MA, Molins A, Camacho M, Vila L, Nomdedeu JF, Mangues R, León J: Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc. Mol Cancer Ther; 2006 May;5(5):1166-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc.
  • We have tested the antiproliferative activity of these compounds on a panel of cell lines derived from myeloid and lymphoid leukemias (K562, Raji, HL-60, and Molt4).
  • The cytotoxic IC(50) in these cell lines ranged between 14 and 50 micromol/L, but it was higher for nontransformed cells such as 32D, NIH3T3, or human leukocytes.
  • All compounds showed cytotoxic activity on all tested cell lines, accompanied by DNA synthesis inhibition and arrest in the G(0)/G(1) phase.
  • Bobel-16, Bobel-4, and Bobel-24 induced a caspase-independent cell death in K562 and Raji cells, accompanied by chromatin condensation, cytochrome c release, and dissipation of mitochondrial membrane potential in a concentration-dependent manner and production of reactive oxygen species.
  • As the proto-oncogene MYC is involved in mitochondrial biogenesis and survival of leukemia cells, we tested its effect on bobel activity.
  • In conclusion, Bobel derivatives induce a caspase- and Bcl-2-independent cell death in which mitochondrial permeabilization and MYC down-regulation are involved.
  • Bobels may serve as prototypes for the development of new agents for the therapy of leukemia.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Leukemia / metabolism. Mitochondria / drug effects. Phenols / chemistry. Phenols / pharmacology. Proto-Oncogene Proteins c-myc / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Arachidonate 5-Lipoxygenase / metabolism. Biphenyl Compounds / chemical synthesis. Biphenyl Compounds / chemistry. Biphenyl Compounds / pharmacology. Caspases / metabolism. Cell Cycle / drug effects. Cell Membrane Permeability / drug effects. Cyclooxygenase 2 Inhibitors / metabolism. Cyclooxygenase 2 Inhibitors / pharmacology. Dose-Response Relationship, Drug. Down-Regulation / drug effects. HL-60 Cells. Humans. K562 Cells. Lipoxygenase Inhibitors. Mice. NIH 3T3 Cells. Prostaglandin-Endoperoxide Synthases / metabolism. Reactive Oxygen Species / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731748.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2,6-diisopropyl-4-iodophenol; 0 / 3-chloro-2,4,6-triiodophenol; 0 / 4-phenyl-2,6-diiodophenol; 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 0 / Cyclooxygenase 2 Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / Phenols; 0 / Proto-Oncogene Proteins c-myc; 0 / Reactive Oxygen Species; 9RB2R81A7U / 2,4,6-triiodophenol; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.22.- / Caspases
  •  go-up   go-down


65. Jain N, Lamanna N: Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. Curr Oncol Rep; 2009 Sep;11(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.
  • Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis.
  • To date, no study has shown a benefit from early cytotoxic therapy for any subgroup of patients with chronic lymphocytic leukemia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3322-9 [18689542.001]
  • [Cites] Blood. 2001 Jul 1;98(1):181-6 [11418478.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2049-53 [12411304.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68 [17707833.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Am J Hematol. 1998 Nov;59(3):223-9 [9798660.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2003-8 [8609709.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1929-32 [9369428.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5913-7 [2503826.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3168-71 [19050308.001]
  • [Cites] Ann Hematol. 2003 Dec;82(12):759-65 [14551737.001]
  • [Cites] Cancer. 1977 Aug;40(2):855-64 [890666.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):311-20 [17325891.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3452-9 [8241511.001]
  • [Cites] Blood. 1997 Jun 1;89(11):4153-60 [9166858.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Br J Haematol. 1990 Nov;76(3):352-8 [2261345.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Immunol Today. 1994 Jun;15(6):288-94 [7520700.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):452-3 [12167696.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4634-41 [17008705.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Leukemia. 2005 May;19(5):750-8 [15759031.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Leukemia. 2004 Mar;18(3):476-83 [14712287.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):491-7 [19075280.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2516-22 [9116297.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Br J Haematol. 1996 Feb;92(2):382-8 [8603004.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3175-82 [16014569.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):373-80 [19117034.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):995-1004 [19188171.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1902-3 [11263445.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 19679010.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38
  • [Number-of-references] 50
  •  go-up   go-down


66. Barredo J, Ritchey AK: Controversies in the management of central nervous system leukemia. Pediatr Hematol Oncol; 2010 Aug;27(5):329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the management of central nervous system leukemia.
  • Although few (<5%) patients with acute lymphoblastic leukemia (ALL) actually present with overt CNS leukemia, without prophylactic CNS-directed treatment, over 50% will develop CNS disease.
  • Although great progress has been made, we continue to struggle with management of CNS leukemia.
  • This commentary will address issues of CNS leukemia treatment at diagnosis and at relapse.
  • Topics that will be addressed include (1) CNS 2 status at diagnosis-definition and treatment;.
  • (2) CNS leukemia at diagnosis--treatment with radiation therapy;.
  • (3) isolated relapse of leukemia in the CNS--treatment of early and late relapse; and (4) opportunities for future research in CNS relapse of ALL.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Chemoprevention / methods. Disease Management. Humans. Recurrence

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for central nervous system leukemia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20469977.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


67. Rivero-Vergne A, Berrios R, Romero I: Cultural aspects of the Puerto Rican cancer experience: the mother as the main protagonist. Qual Health Res; 2008 Jun;18(6):811-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a phenomenological approach, in-depth interviews were conducted with acute lymphoblastic leukemia (ALL) patients, their mothers, and their oncology treatment team (18) at a children's hospital in Puerto Rico.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Mothers / psychology. Parent-Child Relations / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503022.001).
  • [ISSN] 1049-7323
  • [Journal-full-title] Qualitative health research
  • [ISO-abbreviation] Qual Health Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Wu S, Korte A, Kebelmann-Betzing C, Gessner R, Henze G, Seeger K: Interaction of bone marrow stromal cells with lymphoblasts and effects of predinsolone on cytokine expression. Leuk Res; 2005 Jan;29(1):63-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we characterized BM stromal cells isolated from children with acute lymphoblastic leukemia and determined the effect of the interaction between stromal cells and lymphoblasts on cytokine expression as well as the effect of prednisolone using mono- and co-culture models.
  • These findings indicate that stromal cells are important components involved in malignant hematopoiesis and also in response to therapy.

  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15541477.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


69. Greenfield HM, Hunt R, Lee LK, Jowitt SN: B-cell chronic lymphocytic leukaemia with extensive lytic lesions. Eur J Haematol; 2006 Apr;76(4):356-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell chronic lymphocytic leukaemia with extensive lytic lesions.
  • [MeSH-major] Bone Resorption / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519709.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


70. Nabhan C: Frontline therapy for chronic lymphocytic leukemia: the dilemma continues. Clin Cancer Res; 2008 Jul 1;14(13):4353
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • (PMID = 18594019.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


71. Al'-Radi LS, Samoĭlova RS, Tikhonova LIu, Diagileva OA, Obukhova TN, Kaplanskaia IB, Gretsov EM, Vorob'ev IA, Kremenetskaia AM, Kravchenko SK: [Combination of chronic lymphoid leukemia and hairy cell leukemia]. Ter Arkh; 2006;78(7):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of chronic lymphoid leukemia and hairy cell leukemia].
  • [MeSH-major] Leukemia, Hairy Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944757.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


72. Lazarevic V, Wahlin A, Hultdin M, Zhan F, Shaughnessy J: Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1. Leuk Lymphoma; 2006 Sep;47(9):1987-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.
  • [MeSH-major] Bone Diseases / diagnosis. Diagnosis, Differential. Intercellular Signaling Peptides and Proteins / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065022.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


73. Walton JA, Lydyard PM, Nathwani A, Emery V, Akbar A, Glennie MJ, Porakishvili N: Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype. Br J Haematol; 2010 Jan;148(2):274-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype.
  • We have previously shown an expansion of cytotoxic antigen-experienced CD4(+)T cells (CTLs) that express perforin (PF) in the peripheral blood of patients with B cell chronic lymphocytic leukaemia (B-CLL).
  • CD4(+)PF(+)T cell expansion in B-CLL patients and controls was strongly associated with HCMV seropositivity.
  • We conclude that persistent exposure to HCMV antigens in SP B-CLL patients leads to an expansion of the circulating MHC class II-restricted CD4(+)PF(+)T cell population with effector/memory phenotype.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Cytomegalovirus / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Perforin / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895614.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / RP-PG-0310-1001
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 126465-35-8 / Perforin; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


74. Giacchero D, Monpoux F, Chiavérini C, Lacour JP: [6-mercaptopurine-related hand-foot syndrome in a four-year-old child]. Ann Dermatol Venereol; 2008 Aug-Sep;135(8-9):580-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Syndrome mains-pieds secondaire à la prise de 6-mercaptopurine chez un enfant de quatre ans.
  • We report a case of HFS during treatment of acute lymphoblastic leukemia with 6-mercaptopurine (6-MP) (Purinethol) in a four-year-old child.
  • PATIENTS AND METHODS: A four-year-old boy treated for acute lymphoblastic leukemia developed dry and painful palmar and plantar erythema with fissures.
  • There was no past history of cutaneous disease and no other potential trigger factors.
  • 6-MP is a major reference drug for the management of acute lymphoblastic leukemia.
  • [MeSH-major] 6-Mercaptopurine / adverse effects. Antimetabolites, Antineoplastic / adverse effects. Drug Eruptions / etiology. Erythema / chemically induced. Foot Dermatoses / chemically induced. Hand Dermatoses / chemically induced. Paresthesia / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789293.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


75. Shimonodan H, Nagayama J, Nagatoshi Y, Hatanaka M, Takada A, Iguchi H, Oda Y, Okamura J: Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature. Pediatr Blood Cancer; 2005 Sep;45(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature.
  • BACKGROUND: Osteopathy is one of the common initial symptoms of acute lymphocytic leukemia (ALL) in children and adolescents, but multiple osteolysis accompanied by hypercalcemia is rarely observed.
  • PTHrP expressed in the lymphoblasts may, in itself, confer a survival advantage to lymphoblasts and contribute to the refractory nature of the disease.
  • [MeSH-major] Hypercalcemia / etiology. Osteolysis / etiology. Parathyroid Hormone-Related Protein / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15700250.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  • [Number-of-references] 37
  •  go-up   go-down


76. Krejcí M, Adam Z, Pour L, Brychtová Y, Mayer J, Vorlícek J: [B-cell chronic lymphocytic leukaemia and the similar states]. Vnitr Lek; 2009 Sep;55(9):746-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-cell chronic lymphocytic leukaemia and the similar states].
  • [Transliterated title] Chronická B-lymfatická leukemie a jí podobné stavy.
  • B-cell chronic lymphocytic leukaemia and the similar diseases are seen predominantly in patients above the age 50 years, i.e. at the age when the patients also have other co-morbidities.
  • The knowledge of these diseases on molecular level has improved significantly over the last decade.
  • The aim of the present review is to provide the medical community with the main information on this disease as patients with B-cell chronic lymphocytic leukaemia and similar disease states are of older age and very often suffer from a range of co-morbidities.
  • The aim of the following text is to present a clear overview of the basic information about this group of diseases that might be useful to all physicians who provide care to patients with B-cell chronic lymphocytic leukaemia and similar conditions.
  • Since monoclonal immunoglobulin is sometimes identified in patients with these diseases, it is important to consider these conditions in the differential diagnosis of the states with the presence of monoclonal immunoglobulin.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukemia, Hairy Cell / diagnosis. Leukemia, Prolymphocytic / diagnosis. Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785372.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 41
  •  go-up   go-down


77. Horino S, Rikiishi T, Niizuma H, Abe H, Watanabe Y, Onuma M, Hoshi Y, Sasahara Y, Yoshinari M, Kazama T, Hayashi Y, Kumaki S, Tsuchiya S: Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia. Int J Hematol; 2009 Nov;90(4):483-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia.
  • Immune thrombocytopenic purpura (ITP) has been associated with several hematologic malignancies such as Hodgkin and non-Hodgkin lymphomas and chronic lymphocytic leukemia, but it is rare in children with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Purpura, Thrombocytopenic, Idiopathic / complications. Purpura, Thrombocytopenic, Idiopathic / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Chronic Disease. Female. Humans. Splenectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Immune Thrombocytopenic Purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):372-6 [15700256.001]
  • [Cites] J Pediatr. 1979 Mar;94(3):408-9 [284111.001]
  • [Cites] J Thromb Haemost. 2003 Jul;1(7):1587-92 [12871295.001]
  • [Cites] Am J Med. 2005 Sep;118(9):1026-33 [16164890.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):139-43 [17328716.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jul;27(7):397-9 [16012332.001]
  • [Cites] Cell. 2000 May 26;101(5):455-8 [10850488.001]
  • [Cites] Eur J Haematol. 1993 Oct;51(4):259-61 [7694874.001]
  • [Cites] Haematologica. 1998 Jul;83(7):669-70 [9718878.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):336-44 [14768038.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):44-8 [9482412.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Mar;28(3):170-2 [16679943.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):477-83 [9054651.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Neth J Med. 2006 Nov;64(10):356-63 [17122451.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):719-20 [11127406.001]
  • (PMID = 19816666.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Pamuk GE, Uyanik MS, Demir M, Tekgündüz E, Turgut B, Soy M: Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis. Leuk Res; 2007 Aug;31(8):1149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis.
  • There might be rheumatic manifestations of malignant diseases, especially those of the hematological type.
  • Until now, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in chronic lymphocytic leukemia (CLL) has been reported on only very few occasions.
  • Constitutional symptoms in patients with hematological malignancies should make the physicians consider systemic vasculitis after exclusion of disease-related complications.
  • [MeSH-major] Antibodies, Antineutrophil Cytoplasmic / blood. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Vasculitis, Leukocytoclastic, Cutaneous / blood
  • [MeSH-minor] Aged. Female. Humans. Kidney Diseases / etiology. Kidney Diseases / pathology. Lung Diseases / etiology. Lung Diseases / pathology. Syndrome


79. Gottardi M, Gattei V, Degan M, Bomben R, Zucchetto A, Tecchio C, Laurino L, Zanatta L, Dei Tos AP, Mordacchini M, Canal F, Gherlinzoni F: Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: evidence of simultaneous expansion of two independent clones. Leuk Lymphoma; 2006 May;47(5):885-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: evidence of simultaneous expansion of two independent clones.
  • The simultaneous appearance of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) has been rarely reported, with AML occurring more frequently as a secondary event in patients receiving cytotoxic drugs for a primary lymphoproliferative disorder.
  • To establish whether the two neoplastic cell populations shared some common molecular signature, we performed IgH gene rearrangement studies on CD34 + /CD19- and CD34-/CD19 + immunomagnetically sorted cell populations: only genomic DNA from the CD19 + /CD34- cell fraction revealed the presence of the IgH gene rearrangement.
  • [MeSH-major] Cell Proliferation. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Myeloid / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Acute Disease. Aged. Clone Cells / pathology. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Male


80. Kim SJ, Park TS, Lee ST, Song J, Suh B, Kim SH, Jang SJ, Lee CH, Choi JR: Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci; 2009;39(4):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
  • Therapy-related myelodysplastic syndrome and acute leukemia after treatment with temozolomide have rarely been described in the literature.
  • The cases included anaplastic astrocytoma (4 cases), anaplastic oligodendroglioma (2 cases), low grade astrocytoma (2 cases), low grade oligodendroglioma (1 case), and one case of secondary Philadelphia-positive acute lymphoblastic leukemia in a patient with glioblastoma multiforme.
  • Here we report a novel case of therapy-related myelodysplastic syndrome/acute myeloid leukemia associated with der(1;7)(q10;p10) in a glioblastoma multiforme patient treated with temozolomide.
  • In past reports, karyotypes in cases of therapy-related myelodysplastic syndrome/acute myeloid leukemia mostly demonstrated abnormalities in chromosomes 5 and 7.
  • However, we report a case of temozolomide-related myelodysplastic syndrome/acute myeloid leukemia with der(1;7)(q10;p10), possibly the first reported case, to the authors' knowledge.
  • [MeSH-major] Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced
  • [MeSH-minor] Adult. Aged. Biopsy. Bone Marrow Cells / pathology. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Magnetic Resonance Imaging. Male. Middle Aged. Skin / pathology


81. Matsushita M, Takeuchi S, Yang Y, Yoshino N, Tsukasaki K, Taguchi H, Koeffler HP, Seo H: Methylation of the MLH1 gene in hematological malignancies. Oncol Rep; 2005 Jul;14(1):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genomic DNA was extracted from 31 patients with adult T-cell leukemia/lymphoma (ATL), 9 patients with acute lymphoblastic leukemia (ALL) who had MSI, and 12 leukemia and lymphoma cell lines with MSI.
  • Aberrant methylation of the MLH1 gene was found in 2/31 (6%) ATL patients, and in 1/12 (8%) cell lines with MSI.
  • The MLH1 gene was expressed in the normal peripheral blood samples, but not in the MLH1-methylated cell line KCL22.
  • Demethylation with 5-Azacytidine treatment restored MLH1 expression in the KCL22 cell line.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / pharmacology. Carrier Proteins. Cell Line, Tumor. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic / drug effects. Humans. Jurkat Cells. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. MutS Homolog 2 Protein. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944788.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; M801H13NRU / Azacitidine
  •  go-up   go-down


82. Alonso CN, Meyer C, Gallego MS, Rossi JG, Mansini AP, Rubio PL, Medina A, Marschalek R, Felice MS: BTBD18: A novel MLL partner gene in an infant with acute lymphoblastic leukemia and inv(11)(q13;q23). Leuk Res; 2010 Nov;34(11):e294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BTBD18: A novel MLL partner gene in an infant with acute lymphoblastic leukemia and inv(11)(q13;q23).
  • [MeSH-major] Chromosome Inversion. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598370.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


83. Thygesen LC, Nielsen OJ, Johansen C: Trends in adult leukemia incidence and survival in Denmark, 1943-2003. Cancer Causes Control; 2009 Nov;20(9):1671-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in adult leukemia incidence and survival in Denmark, 1943-2003.
  • The etiology of leukemia is largely unknown.
  • Ecological data indicating trends in incidence and survival can provide information about changes in risk factors, can reflect underlying changes in diagnostic classification, and can measure therapeutic advances.
  • From the records of the Danish Cancer Registry with registration starting from 1943, we calculated age-specific, period-specific, and age-standardized (world standard) incidence rates of chronic lymphoid leukemia (CLL), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML) for persons above the age of 18.
  • Between 1943 and 2003, there were 26,036 cases of leukemia reported.
  • The median survival time increased for all leukemia subtypes throughout the period of study most pronounced for CLL since 1950 and CML since 1990.
  • [MeSH-major] Leukemia / epidemiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672681.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G: Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood; 2009 Feb 26;113(9):1892-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
  • Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).
  • We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse prognosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):139-60 [8449856.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • (PMID = 19109226.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2651008
  •  go-up   go-down


85. Taylor RP, Lindorfer MA: Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol; 2008 Aug;20(4):444-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-CD20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis.
  • Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, for example, NK-cell-mediated killing, may lead to substantial decreases in the immunotherapeutic efficacy of this mAb.
  • Moreover, RTX treatment of patients with chronic lymphocytic leukemia and high levels of circulating B cells can lead to removal of CD20 from the cells, thus allowing them to persist and resist clearance.
  • RTX therapy for several autoimmune diseases has proven to be effective, but in numerous instances there has been little correlation between reductions in disease activity and changes in titers of pathogenic autoantibodies.
  • This paradox may be explained by a separate mechanism: Binding of RTX to B cells generates immune complexes that act as decoys to attract monoycte/macrophages and thus reduce their inflammatory activity in certain autoantibody-mediated diseases.
  • Several second-generation anti-CD20 mAbs with enhanced cytotoxic action have been developed and are being tested in the clinic for treatment of cancer and autoimmune diseases.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Immunol Methods. 2005 Sep;304(1-2):88-99 [16109421.001]
  • [Cites] Clin Immunol. 2005 Dec;117(3):207-13 [16169773.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2600-9 [16456022.001]
  • [Cites] J Exp Med. 2006 Mar 20;203(3):743-53 [16520392.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):394-403 [16622478.001]
  • [Cites] Exp Hematol. 2006 Jun;34(6):753-9 [16728280.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):362-71 [16785532.001]
  • [Cites] J Immunother. 2006 Jul-Aug;29(4):388-97 [16799334.001]
  • [Cites] Am J Med. 2006 Aug;119(8):e3-5 [16887400.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Jan;2(1):20-7 [16932648.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):954-66 [16936269.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2970-82 [16947528.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2648-54 [16825493.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7435-43 [17082663.001]
  • [Cites] Drugs. 2006;66(15):1933-48 [17100405.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3612-22 [17075806.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):29-36 [16735454.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):86-95 [17299446.001]
  • [Cites] PLoS One. 2007;2(3):e326 [17389917.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):361-2 [17395110.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2392-9 [17438098.001]
  • [Cites] Mol Immunol. 2007 May;44(12):3122-31 [17379311.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):1369-80 [17617630.001]
  • [Cites] Autoimmun Rev. 2007 Aug;6(7):497-502 [17643939.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):3351-61 [17709552.001]
  • [Cites] Mol Immunol. 2007 Sep;44(16):3823-37 [17768100.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):4263-71 [17785867.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2561-4 [17475906.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10556-63 [17975000.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Dec;64(3):226-33 [17716905.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):974-80 [18024323.001]
  • [Cites] Arthritis Rheum. 2007 Dec;56(12):3909-18 [18050222.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):361-71 [18097037.001]
  • [Cites] Eur J Immunol. 2008 Jan;38(1):292-8 [18085668.001]
  • [Cites] Arthritis Rheum. 2008 Jan;58(1):5-14 [18163518.001]
  • [Cites] Br J Haematol. 2008 Feb;140(3):303-12 [18045353.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):635-43 [18302712.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Blood. 2001 Aug 15;98(4):952-7 [11493438.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Cancer Immunol Immunother. 2002 Mar;51(1):15-24 [11845256.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1071-9 [12393727.001]
  • [Cites] Haematologica. 2003 May;88(5):482-4 [12745265.001]
  • [Cites] Haematologica. 2003 Sep;88(9):1002-12 [12969808.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3280-8 [14978136.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1659-69 [15210744.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4664-9 [15231679.001]
  • [Cites] J Immunol Methods. 2004 Jun;289(1-2):97-109 [15251416.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2580-9 [15334472.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):501-13 [15693003.001]
  • (PMID = 18585457.001).
  • [ISSN] 0952-7915
  • [Journal-full-title] Current opinion in immunology
  • [ISO-abbreviation] Curr. Opin. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA044579-19; United States / NCI NIH HHS / CA / P30 CA044579; United States / NCI NIH HHS / CA / P30 CA044579-18; United States / NCI NIH HHS / CA / P30 CA044579-19
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 55
  • [Other-IDs] NLM/ NIHMS67374; NLM/ PMC2660201
  •  go-up   go-down


86. Sonoki T, Iwanaga E, Mitsuya H, Asou N: Ovarian relapse seven years after bone marrow transplantation for B-cell acute lymphoblastic leukemia: an unusual Krukenberg tumor. Am J Hematol; 2005 Sep;80(1):75-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian relapse seven years after bone marrow transplantation for B-cell acute lymphoblastic leukemia: an unusual Krukenberg tumor.


87. Lewis FM, Coman DJ, Murdoch BE: Language skills in a child with Leber hereditary optic neuropathy following intrathecal chemotherapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2010 Nov;27(8):626-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Language skills in a child with Leber hereditary optic neuropathy following intrathecal chemotherapy for acute lymphoblastic leukemia.
  • The language skills of a male child with Leber hereditary optic neuropathy (LHON) and coincidentally treated for acute lymphoblastic leukemia (ALL) with intrathecal chemotherapy at the age of 3 years 8 months were comprehensively evaluated twice over a 6-month period approximately 5&#x00BD; years after diagnosis of ALL.
  • In light of the coincidental presentation in the child of a diagnosis of LHON, which may lead to serious vision impairment and increased vulnerability to drug neurotoxicity, coupled with a history of central nervous system (CNS)-directed treatment for ALL resulting in progressive white matter pathology, the study highlights the importance of ongoing monitoring of the child's language development throughout his adolescent years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Language Development Disorders / complications. Language Development Disorders / physiopathology. Optic Atrophy, Hereditary, Leber / complications. Optic Atrophy, Hereditary, Leber / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leber hereditary optic neuropathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795771.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


88. Lee J, Kim Y, Kang CS, Cho DH, Shin DH, Yum YN, Oh JH, Kim SH, Hwang MS, Lim CJ, Yang KH, Han K: Investigation of the bovine leukemia virus proviral DNA in human leukemias and lung cancers in Korea. J Korean Med Sci; 2005 Aug;20(4):603-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of the bovine leukemia virus proviral DNA in human leukemias and lung cancers in Korea.
  • The bovine leukemia virus (BLV) is the causative agent of enzootic bovine leucosis.
  • This study investigated the presence of the BLV in leukemia (179 acute lymphoblastic leukemia, 292 acute myeloid leukemia and 46 chronic myelogenous leukemia cases) and 162 lung cancer patients (139 adenocarcinoma, 23 squamous cell carcinoma) to determine if the BLV is a causative organism of leukemia and lung cancer in Koreans.
  • All 517 cases of human leukemia and 162 lung cancer were negative for a PCR of the BLV proviral DNA.
  • In conclusion, although meat has been imported from BLV endemic areas, the BLV infection does not appear to be the cause of human leukemia or lung cancer in Koreans.
  • [MeSH-major] DNA, Viral / genetics. Leukemia / virology. Leukemia Virus, Bovine / genetics. Lung Neoplasms / virology. Proviruses / genetics
  • [MeSH-minor] Acute Disease. Adenocarcinoma / virology. Cell Line. Humans. Korea. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / virology. Leukemia, Myeloid / virology. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Hypotheses. 1996 Apr;46(4):354-6 [8733164.001]
  • [Cites] Can Vet J. 2001 Mar;42(3):193-8 [11265187.001]
  • [Cites] J Virol Methods. 2002 Jan;99(1-2):33-40 [11684301.001]
  • [Cites] Cancer Res. 1974 Oct;34(10):2745-57 [4370000.001]
  • [Cites] Curr Top Microbiol Immunol. 1984;112:1-19 [6090059.001]
  • [Cites] Br J Ind Med. 1986 Feb;43(2):75-83 [3753879.001]
  • [Cites] Cancer Detect Prev. 1995;19(5):394-404 [7585725.001]
  • [Cites] J Clin Microbiol. 1992 Jan;30(1):185-91 [1370847.001]
  • [Cites] Zentralbl Veterinarmed B. 1992 Feb;39(1):69-77 [1316025.001]
  • [Cites] Cancer Detect Prev. 1994;18(1):9-30 [8162609.001]
  • [Cites] Occup Environ Med. 1994 Aug;51(8):541-7 [7951779.001]
  • [Cites] Am J Ind Med. 1995 Mar;27(3):389-403 [7747745.001]
  • [Cites] Br J Ind Med. 1986 Sep;43(9):597-604 [3756110.001]
  • (PMID = 16100451.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2782155
  •  go-up   go-down


89. Cho YJ, Zhang B, Kaartinen V, Haataja L, de Curtis I, Groffen J, Heisterkamp N: Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia. Mol Cell Biol; 2005 Jul;25(13):5777-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.
  • To investigate if Rac3 contributes to normal or malignant cell function, we generated rac3 null mutants through gene targeting.
  • Bcr/Abl is a deregulated tyrosine kinase that causes chronic myelogenous leukemia and Ph-positive acute lymphoblastic leukemia in humans.
  • Vav1, a hematopoiesis-specific exchange factor for Rac, was constitutively tyrosine phosphorylated in primary lymphomas from Bcr/Abl P190 transgenic mice, suggesting inappropriate Rac activation. rac3 is expressed in these malignant hematopoietic cells.
  • Using lysates from BCR/ABL transgenic mice that express or lack rac3, we detected the presence of activated Rac3 but not Rac1 or Rac2 in the malignant precursor B-lineage lymphoblasts.
  • These data are the first to directly show a stimulatory role for Rac in leukemia in vivo.
  • Moreover, our data suggest that interference with Rac3 activity, for example, by using geranyl-geranyltransferase inhibitors, may provide a positive clinical benefit for patients with Ph-positive acute lymphoblastic leukemia.


90. Yang H, Zhang C, Zhao X, Wu Q, Fu X, Yu B, Shao Y, Guan M, Zhang W, Wan J, Huang X: Analysis of copy number variations of BS69 in multiple types of hematological malignancies. Ann Hematol; 2010 Oct;89(10):959-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent array-based study implicated the presence of copy number variations (CNVs) of BS69 in the genomes of acute myelogenous leukemia.
  • CNVs are present in the general population at varying degrees and have been found to associate with various types of diseases including hematological malignancies.
  • We found significant association between the CNVs of BS69 and these hematological malignancies including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma (MM), and myelodysplastic syndrome (MDS).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425112.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / RNA, Messenger; 0 / ZMYND11 protein, human
  •  go-up   go-down


91. Kern W, Haferlach T, Schnittger S, Schoch C: Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia. Arch Pathol Lab Med; 2005 Mar;129(3):410-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia.
  • Cytomorphologic testing and multiparameter flow cytometry are the mainstays in diagnosing B-cell chronic lymphocytic leukemia, whereas fluorescence in situ hybridization that targets the translocation t(14;18)(q32;q21) often is used to identify follicular lymphoma.
  • Therapy is highly diverse between both diseases.
  • We describe a case with cytomorphologically and immunologically proven B-cell chronic lymphocytic leukemia in which t(14;18)(q32;q21) was found.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737042.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Omodei D, Acampora D, Russo F, De Filippi R, Severino V, Di Francia R, Frigeri F, Mancuso P, De Chiara A, Pinto A, Casola S, Simeone A: Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. Am J Pathol; 2009 Dec;175(6):2609-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma.
  • Here, we investigated OTX1 and OTX2 expression in Non-Hodgkin Lymphoma (NHL) and multiple myeloma.
  • A combination of semiquantitative RT-PCR, Western blot, and immunohistochemical analyses was used to measure OTX1 and OTX2 levels in normal lymphoid tissues and in 184 tumor specimens representative of various forms of NHL and multiple myeloma.
  • OTX1 expression was activated in 94% of diffuse large B-cell lymphomas, in all Burkitt lymphomas, and in 90% of high-grade follicular lymphomas.
  • OTX1 was undetectable in precursor-B lymphoblastic lymphoma, chronic lymphocytic leukemia, and in most marginal zone and mantle cell lymphomas and multiple myeloma.
  • Analysis of OTX1 expression in normal lymphoid tissues identified a subset of resting germinal center (GC) B cells lacking PAX5 and BCL6 and expressing cytoplasmic IgG and syndecan.
  • This study identifies OTX1 as a molecular marker for high-grade GC-derived NHL and suggests an involvement of this transcription factor in B-cell lymphomagenesis.
  • Furthermore, OTX1 expression in a subset of normal GC B cells carrying plasma cell markers suggests its possible contribution to terminal B-cell differentiation.
  • [MeSH-major] B-Lymphocyte Subsets / metabolism. B-Lymphocytes / metabolism. Biomarkers, Tumor / analysis. Germinal Center / metabolism. Lymphoma, Non-Hodgkin / metabolism. Otx Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):22-33 [18097447.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):151-8 [10712946.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3413-20 [11719382.001]
  • [Cites] Nat Immunol. 2002 Apr;3(4):323-8 [11919568.001]
  • [Cites] Curr Opin Genet Dev. 2002 Aug;12(4):409-15 [12100885.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Nat Neurosci. 2003 May;6(5):453-60 [12652306.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10299-303 [12934017.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1862-8 [14615382.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Genomics. 1994 Jul 1;22(1):41-5 [7959790.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2048-59 [9058727.001]
  • [Cites] Development. 1998 Dec;125(24):5091-104 [9811592.001]
  • [Cites] Trends Neurosci. 1999 Mar;22(3):116-22 [10199636.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):703-7 [15705863.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6351-7 [16155019.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):176-86 [16462208.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):499-504 [16734728.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1675-90 [10557039.001]
  • (PMID = 19893048.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / OTX1 protein, human; 0 / OTX2 protein, human; 0 / Otx Transcription Factors
  • [Other-IDs] NLM/ PMC2789631
  •  go-up   go-down


93. Pawińska-Wasikowska K, Balwierz W: [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia]. Przegl Lek; 2010;67(6):361-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
  • [Transliterated title] Zmiany ekspresji determinant komórkowych w trakcie leczenia indukcyjnego dzieci z ostra białaczka limfoblastyczna.
  • Leukemias are the most common malignancy in children, and acute lymphoblastic leukemia (ALL) accounts for 85% of all childhood leukemias.
  • Sequential monitoring of MRD (minimal residual disease) in a set time points during the induction therapy in ALL proves to be a powerful and independent predictor of treatment outcome.
  • Objective was to assess changes in expression of cell antigens during induction treatment of ALL.
  • From May 2005 to January 2008, from among 78 patients with ALL treated in Oncology and Hematology Department, Children's University Hospital in Krakow according to international treatment protocol ALL IC-BFM-2002, 42 were enrolled in assessment of antigens' cells modulation expression during induction.
  • Identification of leukemia associated phenotype (LAP), used for cell analysis in sequential time points, with a set monoclonal antibodies panel, was possible in all analyzed patients.
  • [MeSH-major] Antigenic Modulation / immunology. Antigens, CD / analysis. Neoplasm, Residual / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology


94. Buitenkamp TD, Mathôt RA, de Haas V, Pieters R, Zwaan CM: Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica; 2010 Jul;95(7):1106-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.
  • BACKGROUND: Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and a poor tolerance of methotrexate.
  • DESIGN AND METHODS: We compared methotrexate-induced toxicity and pharmacokinetics in a retrospective case-control study between patients with acute lymphoblastic leukemia who did or did not have Down syndrome.
  • Population pharmacokinetic models were fitted to data from all individuals simultaneously, using non-linear mixed effect modeling.
  • RESULTS: Overall, 468 courses of methotrexate (1-5 g/m(2)) were given to 44 acute lymphoblastic leukemia patients with Down syndrome and to 87 acute lymphoblastic leukemia patients without Down syndrome.
  • Methotrexate clearance was 5% lower in the acute lymphoblastic leukemia patients with Down syndrome (P=0.001); however, this small difference is probably clinically not relevant, because no significant differences in methotrexate plasma levels were detected at 24 and 48 hours.
  • [MeSH-major] Down Syndrome / drug therapy. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


95. Fung KL, Liang RH, Chan GC: Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. Leuk Lymphoma; 2010 Mar;51(3):515-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.
  • Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine.
  • As a consequence, they can help to re-establish the cytotoxic potential of L-asparaginase on ALL cells even under MSCs support.
  • [MeSH-major] Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / pathology. Mesoderm / metabolism. Piperazines / pharmacology. Pyrimidines / pharmacology. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925050.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Tetrazolium Salts; 117038-70-7 / 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide; 5J49Q6B70F / Vincristine; 8A1O1M485B / Imatinib Mesylate; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


96. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Tomlinson IP, Taylor M, Greaves M, Houlston RS: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet; 2009 Sep;41(9):1006-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.
  • To identify risk variants for childhood acute lymphoblastic leukemia (ALL), we conducted a genome-wide association study of two case-control series, analyzing the genotypes with respect to 291,423 tagging SNPs in a total of 907 ALL cases and 2,398 controls.
  • The 10q21.2 (ARID5B) risk association appears to be selective for the subset of B-cell precursor ALL with hyperdiploidy.
  • These data show that common low-penetrance susceptibility alleles contribute to the risk of developing childhood ALL and provide new insight into disease causation of this specific hematological cancer.
  • Notably, all three risk variants map to genes involved in transcriptional regulation and differentiation of B-cell progenitors.
  • [MeSH-major] Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 7. Genetic Predisposition to Disease. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology


97. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, Jones D: TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia; 2006 Feb;20(2):280-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
  • Expression of the human oncogene TCL1 in transgenic mice produces B-cell tumors that resemble chronic lymphocytic leukemia (CLL) suggesting its role in B-cell tumorigenesis.
  • Higher TCL1 levels correlated with markers of the 'pre-germinal center' CLL subtype including unmutated VH status (P=0.005), ZAP70 expression (P=0.007), and presence of chromosome 11q22-23 deletions (P=0.04).
  • TCL1 expression patterns in CLL are complex and highly dynamic and appear to reflect both the histogenetic subtypes of the disease and the growth parameters of individual tumors.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Animals. Cell Differentiation / drug effects. Cell Proliferation / drug effects. Humans. Immunohistochemistry. In Vitro Techniques. Interleukin-4 / pharmacology. Mice. Mice, Transgenic. Mutation. Oncogenes / genetics. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341048.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human; 207137-56-2 / Interleukin-4
  •  go-up   go-down


98. Zuna J, Zaliova M, Muzikova K, Meyer C, Lizcova L, Zemanova Z, Brezinova J, Votava F, Marschalek R, Stary J, Trka J: Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer; 2010 Oct;49(10):873-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin.
  • The ETV6/ABL1 (TEL/ABL) fusion gene is a rare aberration in malignant disorders.
  • Only 19 cases of ETV6/ABL1-positive hematological malignancy have been published, diagnosed with chronic myeloid leukemia, other types of chronic myeloproliferative neoplasm, acute myeloid leukemia or acute lymphoblastic leukemia (ALL).
  • A thorough review of the literature and an analysis of all published data, including the three new cases, suggest poor prognosis of ETV6/ABL1-positive acute leukemias.
  • The course of the disease in the two pediatric patients is characterized by minimal residual disease monitoring, using quantification of both the ETV6/ABL1 transcript and immunoreceptor gene rearrangements.
  • Eosinophilia could not be confirmed as a hallmark of the ETV6/ABL1-positive disease.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Tyrosine Kinases / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589932.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TEL-ABL fusion protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


99. Lyu CJ, Rha SY, Won SC: Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Yonsei Med J; 2007 Apr 30;48(2):171-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.
  • But, until today, the importance of theses factors on leukemia, especially childhood acute lymphocytic leukemia (ALL) has received limited attention.
  • PATIENTS AND METHODS: Bone marrow plasmas at diagnosis from 33 ALL patients (median age 5.9 years; range 1.8-13.9 years) were used for analysis.
  • [MeSH-major] Bone Marrow / blood supply. Neovascularization, Pathologic / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):309-13 [10607717.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4303-7 [16123221.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2240-5 [10979972.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):83-8 [11699225.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3381-4 [11705851.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):219-24 [11999550.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):991-8 [12199777.001]
  • [Cites] J Mol Med (Berl). 2003 Jan;81(1):20-31 [12545246.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Mar;45(3):227-44 [12633837.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):163-4 [12823361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]
  • [Cites] Stem Cells Dev. 2004 Oct;13(5):484-95 [15588506.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1383-95 [15471951.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Oncology. 2000 Feb;58(2):169-74 [10705245.001]
  • (PMID = 17461513.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC2628125
  •  go-up   go-down


100. Muramatsu T, Nakamura Y, Shibuya A, Suzuki H, Ando M: [Recurrence of severe hypophosphatemia associated with tumor neogenesis in a patient with acute lymphocytic leukemia who experienced acute renal failure due to tumor lysis syndrome]. Nihon Jinzo Gakkai Shi; 2008;50(5):602-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence of severe hypophosphatemia associated with tumor neogenesis in a patient with acute lymphocytic leukemia who experienced acute renal failure due to tumor lysis syndrome].
  • We report a 47-year-old male patient with acute lymphocytic leukemia (ALL) who showed recurrent severe hypophosphatemia.
  • Thereafter, severe hypophosphatemia (serum phosphorus concentration less than 0.7 mg/dL) was observed several days before an acute rise in peripheral lymphoblast cell counts due to recurrence of ALL.
  • [MeSH-major] Acute Kidney Injury / etiology. Hypophosphatemia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tumor Lysis Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18767489.001).
  • [ISSN] 0385-2385
  • [Journal-full-title] Nihon Jinzo Gakkai shi
  • [ISO-abbreviation] Nihon Jinzo Gakkai Shi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement